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The normal prostate
The prostate is the largest accessory gland of the male reproductive system. 
(Figure 1) The healthy adult prostate is about the size of a chestnut and conical 
in shape. In general, it measures 20 ml in volume, though it can become five or 
six time that size with increasing age. The prostate is shaped like an inverted 
pyramid and lies between the bladder and the pelvic floor (1).  The prostate 
supplies about 30% of the volume of the seminal fluid. The normal prostate is 
composed of epithelial glands and stroma. These glands represent the terminal 
tubular portion of long tubulo-alveolar glands that radiate from the urethra. The 
glands are lined by two cell layers: an outer low cuboidal layer and an inner layer 
of tall columnar mucin-secreting epithelium. Half of the volume of the prostate is 
occupied by the fibromuscular stroma between the glands. 
Figure 1. Male reproductive system
The prostate zones
The prostate consist of several zones, the peripheral zone, the central zone and 
the transition zone (Figure 2). Prostate cancer mainly occurs in peripheral zone, 
whereas benign prostatic hyperplasia (BPH) merely occurs in transition zone. 
BPH is a benign enlargement of the prostate. The concept of zonal anatomy was 
first described by McNeal (2,3). 
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Figure 2. The human prostate zones
The peripheral zone
The peripheral zone forms about 70% of the glandular portion of the prostate 
and is located at the dorsal and dorso-lateral side of the prostate. Most prostate 
cancers arise from this zone. In order to establish whether a patient has a diag-
nosis of prostate cancer, transrectal ultrasound guided biopsies of the prostate 
are taken mostly from peripheral zone.
The central zone
The central zone represents about 25% of the prostate gland. It is wedge shaped 
and has its broad base just below the bladder. The ejaculatory duct runs in the 
middle of the central zone.
The transition zone
The transition zone, which is located peri-urethrally and more centrally in the 
prostate, forms about 5% of the normal prostate. This part of the prostate can 
grow extensively in elderly men with BPH (benign prostatic hyperplasia) (1). 
BPH is a benign prostate enlargement and occurs almost exclusively in the 
transition zone.
Less than 30% of prostate cancers consist of transition zone tumors, they have 
lower biochemical recurrence rates and are less malignant than the tumors 
originating in the peripheral zone (4,5) 
Hormonal environment of the prostate gland 
In the adult, prostate gland size is preserved through a homeostatic balance be-
tween the process of cell renewal and cell death. This balance is, among others, 
regulated by hormones secreted by the endocrine system, mainly androgens, 
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of which testosterone is the major circulating form.
The hormonal environment of the prostate gland is largely dependent upon the 
part of the endocrine system that involves the hypothalamic-pituitary-testicular 
axis.
The hypothalamus, initiates a series of events that leads to the secretion of 
testosterone (Figure 3). Luteinising hormone-releasing hormone (LHRH), and 
corticotrophin-releasing hormone (CRH), that acts on the pituitary gland to re-
lease additional hormones, are locally released by the hypothalamus.
The hormones secreted by the pituitary gland are luteinising hormone (LH), 
follicle stimulating hormone (FSH) and adrenocorticotrophin (ACTH). These 
hormones have their effects on the testes and adrenal glands when entering 
the circulation. Upon this stimulation, the Leydig cells of the testes then start 
producing testosterone.
Figure 3. Men who are 5 alpha-reductase deficient are unable to convert testosterone into 
DHT and these men don’t develop a prostate.
 
In the prostate, testosterone is metabolised to dihydrotestosterone (DHT) by the 
enzyme 5 alpha-reductase. DHT binds to the androgen receptor (AR) within the 
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glandular cells. Inside the cell nucleus, the AR-DHT complex targets specific 
DNA sequences known as androgen response elements (AREs). These AREs 
activate cell functions, including growth and proliferation, which play a major 
role in prostate cancer.
Prostatic Hyperplasia
BPH is a benign enlargement of the prostate and is a common condition among 
aging men. BPH is rarely life threatening when treated. Several types of BPH 
can be distinguished, which vary from stromal, fibromuscular, muscular fibroad-
enomatous to fibromyoadenomatous nodules occurring almost exclusively within 
the transition-zone of the prostate (4). Possibly 25% of men have some degree 
of hyperplasia at fifty years of age and approximately 80% of 70-80 year old 
men have histological evidence of BPH (6). However, in only about 10% of 
these cases will BPH be symptomatic and severe enough to require surgical or 
medical therapy.
Available drugs like finasteride and episteride, which act to inhibit the enzyme 
5-alpha reductase, block the growth-promoting androgenic effect and diminishes 
prostatic enlargement (7). Another class of drugs used to treat BPH are the al-
pha adrenergic blockers, which cause relaxation of smooth muscle in prostate 
and help to relieve obstruction (8). Drug therapy must be continued to remain 
effective.
Histologically, nodular prostatic hyperplasia consists of nodules of ducts and 
intervening stroma. Most of the hyperplasia is composed of glandular prolifera-
tion, but the stroma is also increased, and in some cases may predominate (9). 
The ducts may be more variably in size. Nodular hyperplasia is not a precursor 
to carcinoma (10).
Prostatic Adenocarcinoma
Although with lower prevalence than benign disease, adenocarcinoma of the 
prostate is common. It is the most frequent non-skin malignancy in elderly men. 
Prostatic adenocarcinoma is rare before the age of 50, but autopsy studies of 
unrelated cases have found prostatic adenocarcinoma in approximately 70% of 
men in their 60s (11). Some of these carcinomas are small and clinically insig-
nificant and do not pose a threat to life or health, however, prostatic adenocar-
cinoma is second only to lung carcinoma as a cause for tumor-related deaths 
among males (12).
Men with a higher likelihood of developing a prostate cancer (in the U.S.) include 
those of older age, African American heritage, and family history of this disease. 
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Those with an affected first-degree relative have double the risk (13).
Prostate cancers may be detected by digital rectal examination, by ultrasonography 
(transrectal ultrasound), or by screening with a blood test for prostate specific 
antigen, PSA (13-15). Rectal examinations are poor methods to reliably detect 
all prostate cancers, particularly the small tumors. PSA, on the other hand is 
reasonably sensitive (80%), though often with false positives with respect to 
cancer diagnosis (16).
PSA is a glycoprotein produced almost exclusively in the epithelium of the 
prostate gland. The PSA serum level in older men is usually less than 3 ng/mL 
(normal ranges vary depending upon which assay is used). A mildly increased 
PSA (3 to 10 ng/ml) in a patient with a very large prostate can be due to nodular 
hyperplasia, or to prostatitis, rather than carcinoma. A rising PSA (more than 
0.75 ng/mL per year) is suspicious for prostatic carcinoma, even if the PSA is 
in the normal range. Transrectal needle biopsy, often guided by ultrasound, is 
needed to confirm the diagnosis after suspicion of prostate cancer. Incidental 
carcinomas can be found in prostate tissue from transurethral resections for 
nodular hyperplasia or cysto-prostatectomies or Millen (16).
Cytological characteristics of adenocarcinoma include enlarged round, hyper-
chromatic nuclei that have a single prominent nucleolus. Less differentiated 
carcinomas have fused glands called cribriform glands, in addition to solid nests 
or sheets of tumor cells, and many tumors have two or more of these patterns. 
Prostatic adenocarcinomas almost always arise in the peripheral zone of the 
prostate and are often multifocal (17).
Prostatic adenocarcinomas are usually graded according to the Gleason grading 
system based on the pattern of growth. There are 5 grades (from 1 to 5) based 
upon the architectural patterns, in which adenocarcinomas of the prostate are 
given two grades, based on the most abundant grade and second most abun-
dant grade. These two grades are added to get a final score ranging from 2 to 
10. The stage is established by the size and location of the cancer, whether it 
has invaded the prostatic capsule or seminal vesicle, and whether it has metas-
tasized (18). The grade and the stage correlate well with each other and with 
the prognosis. The prognosis of prostatic adenocarcinoma varies broadly with 
tumor stage and grade. In general, cancers with a Gleason score of <6 are low 
grade and not aggressive. Advanced prostatic adenocarcinomas typically cause 
urinary obstruction, metastasize to regional (pelvic) lymph nodes and to the 
bones, causing blastic metastases in most cases. Metastases to the lungs and 
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liver are seen in a minority of cases (19).
Epithelial to mesenchymal transition
Epithelial to mesenchymal transition (EMT) is an interconversion between epi-
thelial and mesenchymal states, in which polarized epithelial cells can obtain 
mesenchymal characteristics that resembles those of fully differentiated fibro-
blasts or myofibroblasts (20). These fibroblastic cells are capable of locomotion 
and induce cellular changes including alteration of epithelial cell-cell and cell-
matrix adhesion contacts of their active cytoskeleton. In addition, molecular 
programs which are able to both degrade and integrate the extracellular matrix 
(ECM) are activated by these fibroblasts. These capabilities in matrix remodelling 
enable motile transitioning cells to invade through basement membranes and 
continue migration in ECM, a process that is often identified in tumor invasive-
ness (21). The EMT program has been identified to trigger a variety of tissue 
remodelling events during development, including formation of the secondary 
oral palate, in which differentiated epithelial cells undergo an EMT and so be-
come integrated into the mesenchymal compartment, thereby completing the 
program of palatogenesis (22). Interestingly, Foxf2 knockout mice have a defect 
in secondary oral palate formation, suggesting a role for Foxf2 in EMT (Chapter 
5). Secondary palate formation occurs in relatively well-differentiated epithelial 
cells that are destined to become defined mesenchymal cell types. This raises 
the possibility that EMTs may also be induced under certain physiological or 
pathological conditions in adult tissues, including tumor invasion and metasta-
sis processes. EMT related alterations occur in coordination with other cellular 
programs, such as cell survival and proliferation. Examples of genes involved 
in the EMT program are transcription factors Twist, Snail, Slug and ZEB2, all 
able to induce EMTs in epithelial cells. In EMT, loss of E-cadherin is consistently 
reported in both development and tumor metastasis, whereas mesenchymal 
makers as N-cadherin, vimentin and fibronectin are often up-regulated. Fur-
thermore, exposure of TGFβ1 in human mammary epithelial cells, also lead to 
induction of an EMT (23). Evidence of self-renewing and stem-like cells within 
tumors was provided by studies in neoplastic cells (24). These cells have been 
called cancer stem cells or tumor initiating cells and are suggested to behave in 
a similar way as mesenchymal-appearing cells, which have just undergone EMT 
(23). Understanding the changes that occur in the microenvironment of prostate 
cells undergoing EMT, will be critical to understand how primary prostate tumor 
cells convert to metastatic cells.
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Forkhead transcription factors
Forkhead / winged helix proteins belong to a large family of evolutionary conserved 
110 amino acid DNA binding proteins (25,26). It has been more than a decade 
since discovery of the Drosphila transcription factor forkhead and subsequent 
identification of the mamalian orthologues of the forkhead DNA binding domain 
(27). Forkhead genes encode a subgroup of helix-turn-helix class of proteins. 
The arrangement of loops connecting the β strands that flank one of the three α 
helices, gives rise to a butterfly like appearance, hence the name “winged-helix” 
transcription factors (28). It is a relatively invariant structure, with most amino 
acids being conserved between family members. This has made it difficult to 
understand the molecular mechanisms underlying the sequence specificity of the 
DNA-binding domains. All Forkhead factors can bind DNA, the functional effect of 
this can be either the activation or the inhibition of gene transcription. In contrast 
to the DNA-binding domains, there is almost no sequence homology between 
the transactivation or repression domains of members of the forkhead family, 
and little is known about their interactions with the transcriptional machinery. The 
forkhead family has been implicated in a variety of cellular processes and they 
play a role in embryonic development and also in disease.
Evolution
Forkhead genes have thus far been found in opisthokont organisms (animals + 
fungi), including several species of ascomycetic fungi and a wide variety of meta-
zoans. Their absence in the Arabidopsis genome and failure to identify forkhead 
genes in any protist, support the idea that this gene family is found exclusively 
in animals and fungi (29). Forkhead genes contribute in the regulation of many 
developmental and metabolic processes. A number of forkhead proteins are 
involved in several morphogenetic processes during embryonic development, 
and their meaning is indicated by correlation between forkhead number and 
anatomical complexity of the animals (30). A model for Fox cluster evolution has 
been visualized by expression in the bilateria. This model depicts the evolution 
of the FoxL1/FoxC/FoxF/FoxQ1 genes and their expression domains (Figure 4). 
Organization of Fox genes in five extant taxa were shown at the tips of the tree. 
Colour coding indicated the expression of FoxC, FoxF and FoxL1 in the meso-
derm, and FoxQ in the endoderm. This model predicts that a four-gene cluster 
has evolved by the base of the bilaterians, and was co-ordinately expressed 
in mesendodermal derivatives. Some gene loss is also inferred, including one 
FoxQ1 and one FoxL1 gene in humans (following block duplication of the cluster), 
and FoxQ1 in the lineage leading to insects.
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Figure 4. A model for the evolution of FoxF, FoxC, FoxL1 and FoxQ1 genes and their expres-
sion domains (31). The tree shows a basic phylogeny of the bilateria. Organization of Fox 
genes in six existing taxa is shown at the tips of the tree, and to the right of this are illustrative 
representations of embryos in transverse section with dorsal to the top. The model predicts 
that a four-gene cluster had evolved by the base of the bilaterians and was expressed in 
endo-mesodermal derivatives. Some gene loss is also inferred, including one FoxQ1 and one 
FoxL1 gene in humans (following block duplication of the cluster), and FoxQ1 in the lineage 
leading to protostomes.
Nomenclature
The nomenclature of forkhead transcription factors was revised in 2000 (32). 
Fox (for “Forkhead box”) is used as root symbol and officially states that the 
same name is utilized for orthologous genes in different species and reflects 
phylogenetic relationships by including a letter that indicates subfamily. Within 
a subfamily, each gene is identified by a number (e.g.FOXF2), the typography 
follows the conventions used in other species (FOXF2 in Homo sapiens, Foxf2 
in Mus musculus and FoxF2 in all others) and proteins are distinguished from 
genes by the use of roman type (e.g. FoxF2). New and old name and other useful 
information concerning nomenclature can be found on http://biology.pomona.edu/
fox/. The most commonly used synonyms for human, mouse and rat forkhead 
genes are listed in table 1.
Basal Bilaterian
FoxQ1 FoxF FoxC FoxL1 Gene deletion
Block duplication
Tandem duplication
Basal chordate
Ancestral gene organisation
Gene organisation
in living taxa
CNS
FoxC
FoxL1
FoxF
FoxQ1
Cephalochordates
Ecdysozoa
B. floridae
A. melifera
S. mediterranea
H. sapiens
A. gambiae
D. melanogaster
Vertebrates
Lophotrochozoa
Protostomes
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Table 1. The more commonly used synonyms of human, mouse, and rat Fox names
Scope of this thesis
Prostate cancer (PC) and benign prostatic hyperplasia (BPH) are two common 
prostate diseases originating in the prostate peripheral and transition zone. When 
this project started, the molecular basis for the differences between the prostate 
zones was unknown. We hypothesized that the predisposition of prostate cancer 
in peripheral zone and BPH in the transition zone originates from preexisting 
molecular differences in the normal zones. The gene expression profiling studies 
that had been conducted on PC and BPH mainly focused on the expressing 
profiles associated with the diseases and not on the confinement of the diseases 
to the different prostate zones. In Chapter 2 of this thesis we investigate gene 
expression of the human prostate zones.
 
Two important genes that emerged from the zonal expression data were FOXF1 
and FOXF2. We hypothesize that these transcription factors are imperative in 
clarifying prostate diseases. Not much was known about the general expression 
of forkhead transcription factors in the prostate. Chapter 3 describes the analysis 
of 12 forkhead transcription factors in normal prostate, prostate cancer, prostate 
metastases, androgen-dependent and androgen-independent xenografts and 
several prostate cell lines. In this analysis we observed that FOXF2 was of interest 
FoxF2  FREAC-2, Lun
FoxG1 BF-1
FoxH1 FAST1
FoxI1 FREAC-6, HFH-3, Fkh10
FoxJ1 HFH4
FoxK1  ILF, MNF
FoxL1 FREAC-7, Fkh6
FoxM1 Trident, HFH-11, INS1
FoxN1 Whn
FoxN2 HTLF
FoxO1 FKHR
FoxO3 FKHRL1
FoxO4 AFX1
FoxP1 QRF1
FoxQ1 HFH-1, HFH1L
FoxA1 HNF3
FoxA2 HNF3
FoxA3 HNF3
FoxB1 Fkh5
FoxB2 Fkh4
FoxC1 FREAC-3, FKHL7, Mf1, Fkh1
FoxC2 Mfh1
FoxD1 FREAC-4, BF2
FoxD2 FREAC-9, Mf2
FoxD3 HFH2, Genesis
FoxD4 FREAC-5, Fkh2, HFH-6
FoxE1 FKHL15, TTF2
FoxE2 HFKH4
FoxE3 FREAC-8
FoxF1  FREAC-1, HFH-8
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because it was lower expressed in prostate cancer compared to normal prostate 
and higher expressed in transition zone compared to peripheral zone.
In Chapter 4, we studied the FOXF2 pathway in the human prostate stroma. To 
accomplish this, siRNA studies directed against FOXF2 were performed to identify 
the target genes of FOXF2 by microarray analyses. After exploring FOXF2 gene 
expression and FOXF2 regulated pathways in human adult prostate in Chapter 4, 
we explored the potential role for Foxf2 in prostate development. We investigated 
the phenotypic changes in the urogenital sinus (UGS) of Foxf2 knockout and wild-
type mice. Chapter 5 will discuss the effect of Foxf2 knockdown in UGS anatomy. 
Chapter 6 discusses the results of this thesis and future perspectives.
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Abstract
Objective. The prostate consists of several zones; the peripheral zone, the 
transition zone and the central zone. Aggressive tumors predominantly occur in 
the peripheral zone, whereas benign prostatic hyperplasia (BPH) occurs almost 
exclusively in the transition zone. To understand the basis of these prostate 
diseases and their confinement to a specific zone, gene expression patterns in 
the unaffected peripheral and transition prostate zones were investigated.
Methods. Expression profiling of both prostate zones was performed by microarray 
analyses. RT-PCR of the top 18 genes confirmed the microarray analyses. RT-
PCR performed with common cell type markers indicated that the differential 
expression between the two zones was not caused by an unequal distribution of 
different cell types. Primary stromal (PrSC) and epithelial prostate cells (PrEC) 
were used to study cell type expression in the 12 highest differentially expressed 
zonal-specific genes.
Results. 346 genes were identified that were preferentially expressed in the 
transition or peripheral zone. Few of the transition zone-specific genes, including 
ASPA, FLJ10970 and COCH were also observed to be stroma-specific. Data-
base comparisons with other microarray studies showed that gene expression 
profiles of prostate cancer and BPH correlate with the expression profiles of the 
peripheral and transition zone, respectively. 
Conclusion. Our data indicate that gene expression differs between peripheral 
and transition zone and we speculate that stromal-epithelial interactions could 
be responsible for the distinct zonal localization of prostate diseases.
Introduction
Prostate cancer (PC) and benign prostatic hyperplasia (BPH) are two common 
prostate diseases (1). BPH is a benign enlargement of the prostate and it is 
estimated that up to 80% of 70-80 year old men have histological evidence of 
BPH (2). When treated, BPH is rarely life threatening. Several types of BP fibro-
myoadenomatous nodules occurring almost exclusively within the transition zone 
of the prostate (3). Prostate cancer is the most frequently diagnosed cancer in 
Western countries and is the second leading cause of cancer deaths in these 
parts of the world. The majority of prostate cancers occur in the peripheral zone, 
which is located at the dorsal and dorso-lateral side of the prostate. Less than 
30% of prostate cancers consist of transition zone tumors, they have lower bio-
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chemical recurrence rates and are less malignant than the tumors originating 
in the peripheral zone (4). BPH, on the other hand, occurs almost exclusively 
in the transition zone, which is located peri-urethrally and more centrally in the 
prostate. BPH can be an overgrowth or hyperplasia of both stromal and epithelial 
compartments and does not involve prostatic intraepithelial neoplasia (PIN). PC 
evolves from PIN and/or other atypically proliferation lesions (5). The molecular 
basis for the differences between the prostate zones is unknown. Given that 
the diseases have a strong preference for a specific zone, we assume that this 
predisposition originates from preexisting molecular differences in the normal 
zones. Up till now, several gene expression profiling studies have been conducted 
on PC and BPH, reviewed by Nelson et al. (6). These studies however, focused 
on the expressing profiles associated with the diseases and not on the confine-
ment of the diseases to the different prostate zones. 
Morphologically, pathologists consider the transition zone of the prostate similar 
to the peripheral zone (7). Other studies also showed that the transition zone and 
the peripheral zone are morphologically much alike. The zones of the prostate 
gland consist of a complex environment of both stromal and epithelial cells. The 
complexity of the interaction between both these cell types has been the focus 
of exploration in the past decades, and remains an intensively studied field of 
research (8). Therefore it is very important to take cell type distribution and 
cell type characteristics into consideration when studying the prostate zones. 
Cunha et al. (9) demonstrated that stromal cells have the ability to modulate the 
differentiation pattern of normal prostatic epithelium. This association between 
the two cell types is thought to be critical for normal tissue development and 
maintenance as well as the origin and progression of disease processes like 
PC and BPH.
The present study was performed using oligo microarray analyses to identify the 
differences in gene expression between the normal peripheral and transition 
zone. Expression of the differentially expressed genes was analyzed in stromal 
and epithelial primary cells. Database comparisons with other microarray studies 
were performed to correlate gene expression profiles of cancer and BPH with 
the expression profiles of the normal peripheral and transition zone. Our results 
indicate that the molecular variations in gene expression between the two zones 
could be responsible for the origin of distinct zonal diseases.
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Materials & Methods
Prostate samples
The prostate specimens were obtained from men who suffered from prostate 
cancer and who underwent a radical prostatectomy at the Department of Urology, 
Erasmus MC. (More clinical and demographical information see table 1). 
Table 1. Clinical and demographical information on investigated patients B.S.= before surgery, 
A.S.= after surgery
The experimental protocols were approved by the Erasmus MC Medical Ethics 
Committee according to the Medical Research Involving Human Subjects Act. 
Immediately after surgery, the prostate was examined by a pathologist, who pro-
vided a 0.5-cm thick transverse section of the prostate. Immediately thereafter, 
the samples were snap-frozen in liquid N2-cooled iso-pentane and stored at 
–80°C. Each sample was examined histologically using hematoxylin and eosin-
stained cryostat sections. The frozen sections were independently scored by 
two pathologists for presence of PC and BPH and to affirm zonal origin. Frozen 
sections from both zones without any evidence for BPH or PC were used as a 
template to isolate the normal tissue. Only when both pathologists confirmed 
the zonal specific tissue independent from each other, it was accepted as proper 
tissue. The pathologist scored the number of nuclei of stomal and epithelial 
cells by microscopy. This analysis was semi-quantitative and performed by two 
independent specialists.
Patient Nationality Data of 
surgery
Type of surgery [PSA]
ng/ml 
B.S.
[PSA]
ng/ml 
A.S.
Extra
treatments
P3 Dutch 02-05-2002 Radical prostatectomy 9.1 <0.1 no
P5 Dutch 02-07-2002 Radical prostatectomy 9.6 <0.1 no
P10 Dutch 04-09-2002 Radical prostatectomy 5.1 <0.1 no
P11 Dutch 17-07-2002 Total cystectomy (incl prostate) 2.5 NA
Chemo-
therapy B.S.
P14 Dutch 29-10-2002 Radical prostatectomy 11.0 <0.1 no
P16 Dutch 21-10-2002 Radical prostatectomy 6.0 <0.1 no
P18 Dutch 12-11-2002 Radical prostatectomy 15.0 1.7 no
P19 Dutch 12-11-2002 Radical prostatectomy 6.1 <0.1 no
P27 Dutch 24-07-2003 Radical prostatectomy 22.0 <0.1 Radiation therapy A.S.
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Microarrays       
The oligoarrays were produced at the Erasmus Center for Biomics and contained 
18,584 oligos, representing approximately 15,000 different human genes (Uni-
gene Clusters). The oligo libraries that were spotted on aminosilane slides are 
comprehensive oligo collections designed by Compugen and manufactured by 
Sigma-Genosys. The oligos were printed by a Virtek Chipwriter Professional 
arrayer (Virtek Vision International, Waterloo, Canada). Control spots included 
landmarks, spotting buffer, alien oligos (SpotReport Alien Oligo Array, La Jolla, 
Stratagene), poly d[A]40-60, salmon sperm DNA, and human COT-1 DNA.
RNA isolation, amplification, amino-allyl labeling and array hybridization
RNA was isolated from the prostate samples by homogenization with a cell dis-
rupter (PCU, Kinematica GmbH, Luzern, Switzerland) in RNAbee reagent (Tel-
test Inc, Friendswood, USA). Chloroform was added and centrifuged at 12,000g. 
The water phase was extracted and precipitated with isopropanol. The RNA was 
washed with 75% ethanol and dissolved in RNAse free water. Afterwards, the 
RNA was treated with DNA-free (Ambion, Huntingdon, United Kingdom) for DNA 
digestion. Five µg of total RNA was used for a T7-based linear mRNA amplifica-
tion protocol essentially as described by Van Gelder et al. (10). 
An amino-allyl group was incorporated in the aRNA during the amplification 
step. Afterwards, this amino-allyl group was coupled to an N-hydroxysuccinimide 
modified Cy3 or Cy5 dye (Amersham, NJ, USA).  The aRNA from the transition 
zone was labeled with Cy3 (green) and the aRNA from the peripheral zone of 
the same patient was labeled with Cy5 (red) and hybridized to the same array. 
The experiments were performed in dye swap duplicate. The microarray glass 
slides were pre-hybridized in a 5xSSC, 0.1% SDS, 10% BSA solution for 1 hour 
at 45°C. Thereafter, the slides were washed with water (2x10 minutes) and iso-
propanol (5 minutes) and centrifuged for 4 minutes at 1,000 rpm to dry. Probe 
solutions were hybridized on the array overnight at 45°C in a TECAN HS4800 
hybridization station (TECAN Benelux B.V.). During hybridization the solution 
was continuously moving. Afterwards, the arrays were automatically washed 
in the TECAN with 2xSSC/0.05% SDS (at 42°C), 1xSSC and 0.2xSSC (at RT) 
and dried under a stream of N2-gas. The arrays were scanned in a ScanArray 
Express HT (PerkinElmer Nederland B.V.). Spot intensities were quantified by 
Imagene (BioDiscovery Inc. El Segundo, USA). Spots signals were normalized 
per median subarray. The programs Cluster and TreeView were used for hier-
archical clustering of arrays and genes and visualization. Data were clustered 
by correlation uncentered, average linkage. Comparisons with other microarray 
databases were performed using SRS7 (Lion Bioscience AG, Heidelberg, Ger-
many). Significance analysis of microarrays (SAM) was performed. Statistical 
Chapter 2
26
analysis of the database comparisons were performed according to Bonferroni 
statistical test.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
The reverse transciptase reaction was performed with 1 µg RNA from the prostate 
samples with oligo-T12 primer and pre-incubated for 10 minutes at 70°C. First 
Strand buffer, DTT, dNTPs and RNAsin were added and incubated for 2 minutes 
at 37°C. The RT reaction was initiated by MMLV-RT and incubated for 1 hour 
at 37°C. After this, the reaction was kept 10 minutes at 90°C and immediately 
thereafter frozen.
PCR products were run through 1% agarose gels and scanned with Imago, com-
pact Imagine systems (B&L systems, Maarssen, the Netherlands). The PCR was 
performed with 30 cycles (except for the GAPDH primers, which were performed 
with 25 cycles) and an annealing temperature of 60°C for all primers (Table 2). 
PCR reaction mixtures contained 2.5 µl 0.5 U/µl Taq polymerase, 5 µl 10 x PCR 
buffer, 3 µl 25 mM MgCl2 (Promega Benelux b.v., the Netherlands), 1 µl 10 mM 
dNTPs, 3 µl 100 ng/µl forward and reversed primers (Invitrogen, Breda, the 
Netherlands) and 1 µl cDNA. The gel bands were imaged and quantified using 
ImageQuant (Molecular Dynamics, USA). All experiments were repeated at
least three times. Gene expression data were calculated as ratios between the 
peripheral and transition zone. The data were corrected for GAPDH expression 
and transferred into a 2log ratio and illustrated in TreeView.
PrSC and PrEC cell culture
Primary human prostate epithelial cells (PrEC) and primary human prostate 
stromal cells (PrSC) were purchased and cultured according to manufacturer’s 
guidelines (Clonetics Human and Animal Cell Systems, Cambrex Bio Science 
Walkersvill, Inc). RNA was isolated from the PrSC and PrEC by lysing cells in 
RNAbee reagent. Chloroform was added and centrifuged at 12,000g. The water 
phase was extracted and precipitated with isopropanol. The RNA was washed 
with 75% ethanol and dissolved in RNAse free water. The PrEC and PrSC were 
extracted from whole prostate samples without separation of the zones (informa-
tion provided by Clonetics Inc.). Passages 5 and 7 were used for RNA isolation. 
To minimize selection and adaptation of cells, only early passages 5 and 7 were 
used for isolation and the cells were passaged when they were 70% confluent to 
keep the variation smallest.
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Table 2. Primer sequences for all primers used in the RT-PCR experiments. 
Primers were designed to be, if possible, intron spanning and human-specific (Y, yes; N, no). 
All primers were chosen within 1000 nt from poly-A-tail.
Primer name Primer sequence Intron Human
   Spanning Specific 
SLC14A1 forward 5’ GGAGGAATGTTCATGGC 3’ Y N
SLC14A1 reverse  5’ AGACCCTGGAAGTTAGCTG 3’
THBS4 forward  5’ CAGCACAGACAACTGCC 3’ Y N
THBS4 reverse  5’ GCCAGGATCACTGTTCAT 3’
ASPA forward  5’ ACTCGTTCCATAGCCAAGT 3’ Y N
ASPA reverse  5’ TCGTCTTCCCATCAAGAG 3’
FLJ10970 forward 5’ TCACCCTGGTGAGACTGT 3’ Y N
FLJ10970 reverse 5’ GGCCAAAGATGGAGATAATA 3’
GIG2 forward  5’ ATGGGACTTTGAGAAGAGG 3’ N N
GIG2 reverse  5’ GCCATCTCACTGTTCACAT 3’
ADM forward  5’ CCAGGACATGAAGGGTG 3’ Y Y
ADM reverse 5’ GCTGATCTTGCTCCTGG 3’
TFPI2 forward  5’ GGCTGCAAGTGAGTGTG 3’ Y Y
TFPI2 reverse  5’ CAATCCTCCCTGCTAACA 3’
BST2 forward  5’ AGTACTACCCCAGCTCCC 3’ Y N
BST2 reverse  5’ ACCCGCTCAGAACTGAT 3’
Hepsin forward  5’ ACCAAAGTCAGTGACTTCCG 3’ Y Y
Hepsin reverse  5’ ACAGGAGTCCCAGACAGCAG 3’
EGR1 forward  5’ CCTGCACCCTTGTACAGTGTC 3’ N Y
EGR1 reverse  5’ CATGTCAAGCCATCAGCAAG 3’
GAPDH forward  5’ ACGGGAAGCTTGTCATCA 3’ Y Y
GAPDH reverse  5’ ATGGCATGGACTGTGGTC 3’
PLAB forward  5’ CCTGCAGTCCGGATACT 3’ Y Y
PLAB reverse  5’ CCGAGAGATACGCAGGT 3’
TARP forward  5’ TCACAATGGATCCCAAAGAC 3’ Y Y
TARP reverse  5’ TTGAGGAGCAGGAGGAGG 3’
Collagen forward  5’ CCTCCTGGAGAGAATGGT 3’ Y N
Collagen reverse  5’ CCTATAGCTCCTGGCAAA 3’
Fibronectin forward 5’ GTACATGCTTCGGTCAGG 3’ Y Y
Fibronectin reverse 5’ GGTCTGTAAAGGTTGGCA 3’
Myosin forward  5’ CTGTCCTCTATGGCAATGA 3’ Y Y
Myosin reverse  5’ TCTAGCAGCACTTCCCTC 3’
VWF forward  5’ AGCACCATCTACCCTGTG 3’ Y Y
VWF reverse  5’ CCTTCATGCAGAACGTAAG 3’
Keratin 8 forward  5’ CTCCAGGCTGAGATTGAG 3’ N N
Keratin 8 reverse  5’ TGACGTTCATCAGCTCCT 3’
Chromogranin A forward 5’ TCCAGGTCCGAGGCTACC 3’ Y Y
Chromogranin A reverse 5’ GCCTTGTCTCCTACTCCTGACT 3’
Enolase 2 forward 5’ GACTGAGGACACATTCATTGC 3’ Y Y
Enolase 2 reverse 5’ CCTGATCTGTGATAGTTCACC 3’
Calcitonin forward 5’ GGACTATGTGCAGATGAAGGC 3’ Y Y
Calcitonin reverse 5’ CCTCATGTTAGCATGCCCC 3’
CD4 forward  5’ AGCGGATGTCTCAGATCA 3’ Y N
CD4 reverse  5’ TGCTACATTCATCTGGTCC 3’
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Statistical analyses
Statistical analysis for comparison of the RT-PCR data  (Figure 1b and 2) was 
performed using a paired t-test.  Also the results illustrated in Figure 3 were ana-
lyzed by a paired t-test. The Bonferroni statistical test was applied for analyses 
of database comparisons (Figure 4 and 5). SAM analysis was performed on the 
microarray data. 338 genes were found to be significantly different between the 
prostate zones with a false positive rate of 4.2.  This means that 4.2 genes of 
the 338 significant genes are expected to be false positive.
Figure 1. a) Hierarchical cluster analysis of gene expression of the prostate zones. Overview 
of 346 differentially expressed genes, of which 199 are higher expressed in the peripheral (P, 
red) and 147 are higher expressed in the transition zone (T, green). Rows represent individual 
genes represented as log2 ratio P/T and columns represent the averages of the dye swaps 
of 5 individuals (p11-p27).
b) RT-PCR analysis of 18 genes, selected from the 346 genes, was performed to confirm the 
microarray data. The RT-PCR data are represented as 2log expression ratio of peripheral (P) 
zone versus transition (T) zone. The values are corrected for the internal control GAPDH.
* p<0.05 and ** p<0.01.
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Figure 1c) RT-PCR of 8 differentially expressed genes on the prostate zones from 4 additional 
subjects (P3, P5, P10 and P18) to validate the microarray data.
Results
Gene expression profiling of the prostate zones. 
To survey the molecular variation between the transition and peripheral zone we 
performed microarray analyses. In each experiment, we compared gene expres-
sion of the peripheral and transition zone from the same subject, in total of 5 men. 
The experiments were performed in dye swap duplicate (10 microarrays). 346 
differentially expressed genes were selected [ratio peripheral/transition ≥ 2log
|0.5| and present (unflagged in ≥ 7 of the 10 arrays)]. When the gene was present 
in 7/10 arrays with positive ratio, it means that 7 of the 10 times the gene is higher 
expressed in peripheral zone than in transition zone. 199 genes were higher 
expressed in the peripheral zone and 147 genes were higher expressed in the 
transition zone. Statistical significance analysis of microarrays (SAM) confirmed 
differential expression of 185 genes of the 346 genes, with a false positive rate 
of 4.2. To visualize the relationship between the samples and most differentially 
expressed genes we performed an unsupervised hierarchical clustering (Figure 
1a). The genes that were higher expressed in the transition zone are shown in 
green and the genes that were higher expressed in the peripheral zone are 
shown in red. The top 18 of these differentially expressed genes, 7 from transi-
tion and 11 from peripheral zone, were chosen to verify the microarray data 
with RT-PCR. The expression data from the RT-PCR confirmed the microarray 
profiles and 10 genes were expressed significantly different (P< 0.05) between 
the two zones (Figure 1b).
To further substantiate reproducibility of the microarray data, expression of the 
prostate zones of 4 more subjects (P3,P5,P10 and P18) were analyzed by 
FLJ10970
T
1 2 3 4
P T P T P T P
ASPA
T
c
P
SLC14A1
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GIG2
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RT-PCR with 4 differentially expressed genes from the transition and the periperal 
zone (Figure 1c). This resulted in independent confirmation of the microarray 
data and the RT-PCR experiments of the first set of samples.
Cell Type distribution in the two prostate zones. 
Next, we investigated whether the differential gene expression in the two zones 
is caused by differences in cell type distribution. The frozen sections of the 9 
investigated subjects, were scored for quantity of stroma and epithelium in each 
zone by a pathologist. The average proportion of stromal and epithelial cells was 
approximately 50:50 and this equal distribution was identical in the peripheral and 
transition zone fragments studied. RT-PCR was performed with known markers 
for the most common cell types for 7 subjects. Both zones were analyzed for 
expression of stromal markers (fibronectin, myosin and collagen), epithelial 
markers (keratin 5, keratin 8, prostate specific antigen), neuro-endocrine markers 
(enolase 2, chromogranin A, calcitonin), endothelial marker (von Willebrand 
factor) and a lymphocyte infiltration marker (CD4) (8,11). Keratin 5 is a specific 
basal cell marker and keratin 8 is a luminal epithelium marker. There was no 
significant differential expression of these cell type markers between the two 
prostate zones (Figure 2). The identical distribution of stroma and epithelium in 
the frozen sections, and the equal expression of cell type markers in the RT-PCR, 
suggest that the quantity of cells is not different between the two zones. Instead, 
we would argue that the qualitative differences in cell type characteristics form 
the basis of the observed zonal-specific gene expression.
Figure 2. RT-PCR analyses of common cell type markers to investigate cell type distribution 
between the peripheral and transition zone. The averaged relative expression ratio (± SEM) 
from 7 subjects of at least 3 independent RT-PCR experiments is shown. The RT-PCR data 
were quantified by ImageQuant. A paired t-test was performed showing no significant differ-
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ences in the distribution of the common cell type markers between the two prostate zones. 
P=peripheral zone and T=transition zone.
Differential expression of genes from the prostate zones in PrSC and 
PrEC.
To determine whether the zonal differences can be ascribed to stroma or epithe-
lial characteristics, we studied gene expression of zonal-preferential genes in 
primary human prostate stromal (PrSC) and primary human epithelial prostate 
cells (PrEC). The cell type and purity of these primary cells were verified using 
two stromal markers (fibronectin, myosin) and two epithelial markers (keratin 5, 
keratin 8)(Figure 3a). 
Several of the differentially expressed genes in the transition zone are preferentially 
expressed in PrSC (Figure 3b). The hypothetical protein FLJ10970, COCH and 
ASPA are stroma-specific, with a significant difference of p<0.05.  SLC14A1 and 
FLJ20037 have a more equal expression distribution and BST2 is preferentially 
expressed in epithelial cells (p<0.05). The genes that are higher expressed in the 
peripheral zone (TFPI2, ADM, GDF15 and GIG2) are expressed in both stromal 
and epithelial primary cells. THBS4 was preferentially expressed in stroma.
Figure 3. a) Verification of expression analysis of stromal and epithelial markers in prostate 
stromal PrSC and epithelial PrEC primary cells. RT-PCR analyses of 4 markers were performed 
to verify the purity of primary cells PrSC and PrEC for passages 5 and 7. 
b) RT-PCR analysis of differentially expressed genes from the prostate zones in PrSC and 
PrEC. 6 genes that were higher expressed in transition zone and 6 genes that were higher 
expressed in peripheral zone were analyzed by RT-PCR in PrSC and PrEC. The values are 
averaged percentages of relative gene expression (quantative expression of PrSC/PrEC with 
respect to the total expression x100) from at least 6 RT-PCR experiments (± SEM).
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Differential gene expression in prostate cancer and BPH compared to the 
differentially expressed genes in normal transition and peripheral zone.  
We addressed the question whether the differentially expressed genes from the 
prostate zones are also differentially expressed in the prostate diseases. The 
346 genes differentially expressed in the prostate zones were compared to the 
datasets of Singh et al. (Pca), Dhanasekaran et al. (PCb), and Lapointe et al (PCc) 
(Figure 4) (12,13,14). From each of these datasets, we calculated the average 
expression of each gene of primary PC or BPH samples and compared them 
to the averaged expression of the zonal-preferential genes. Figure 4 illustrates 
that the genes higher expressed in the transition zone tend to overlap with the 
genes that are higher expressed in BPH (p=0.056) and genes lower expressed 
in prostate cancer. Almost all genes that are higher expressed in PC are higher 
expressed in the peripheral zone (p<0.0001).
Differential gene expression in stroma and PC as compared to zonal dif-
ferentially expressed genes
To determine whether there is an expression correlation between the genes as-
sociated with stroma and zonal-preferentially expressed genes, we compared 
our dataset to the data of Stuart et al. (15). In their study, microarray analyses 
were performed on 88 prostate specimens and gene expression was correlated 
to relative content of tumor and stroma. First, we compared the differentially ex-
pressed genes from the prostate zones with the genes associated with stroma 
as defined by Stuart et al. Second, we examined whether genes classified as 
tumor-associated, overlapped with the differentially expressed genes from the 
prostate zones. The comparisons between the datasets were performed via 
unsupervised hierarchical clustering and the results are visualized in TreeView 
(Figure 5). The genes that were higher expressed in the transition zone show a 
significant overlap (p<0.0001) with the genes associated with stroma from Stuart 
et al. Furthermore, the genes that were higher expressed in the peripheral zone 
overlap with the differentially expressed genes in tumor tissue (p<0.0001).
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Figure 4 (left). Comparison between the differentially expressed genes in the prostate zones 
and genes that were higher expressed in PC or BPH. Zonal-specific gene expression (prostate 
zones, PZ) is represented as the average value from 10 microarrays (dye-swap experiments of 
5 subjects) for each gene.  Next to this column, the columns PCa; PC databases from Singh 
et al (13), PCb; PC database from Dhanasekaran et al (14), PCc; PC database from Lapointe 
et al (15), and BPH (14) are presented. The genes were unsupervised clustered. 
Figure 5 (right). Comparison of our dataset to the data of Stuart et al. (16). Rows represent 
346 differentially expressed genes and columns represent the average of 10 microarrays 
(dye-swap experiments of 5 subjects; prostate zones, PZ; P, peripheral zone; T, transition 
zone), stroma-associated genes (stroma) and tumor-associated genes (PC) as defined by 
Stuart et al. (16). The genes were unsupervised clustered.
Discussion
Our analyses were conducted to identify differences in gene expression between 
the transition and peripheral zone of the prostate. Since the prostate diseases 
PC and BPH are preferentially present in the peripheral and transition zone 
respectively, it is our hypothesis that the disease restriction can be explained 
by differences in gene expression profiles between these two zones. Only areas 
of the prostate zones with no suspicion or evidence of histological hyperplasia 
BPH PZ PCa PCc
BPH 
T 
PC 
P 
PCb PZ stroma PC
P
T
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or neoplasia were used for our analyses. Nevertheless, we cannot fully exclude 
that in these normal prostate tissue fragments of elderly men, imperceptible 
changes towards BPH or prostate cancer are present. However, in our opinion 
this tissue is of highest interest for our analyses, since at the age of 50-60 years, 
first signs of hyperplasia and neoplasia become apparent suggesting that this 
is the prostatic milieu supporting initiation and outgrowth of abnormalities. So 
far, most studies focused on gene expression profiling of prostate diseases and 
investigated the molecular variation of PC and BPH compared to normal tissue 
(6). Little attention has been given to the molecular bases of the prostate zones 
as possible explanation for the distinct occurrence of the prostate diseases. Here, 
we demonstrated that there is differential expression between the two normal 
prostate zones using microarray analyses. Statistical evaluation using SAM, sub-
stantiated differential expression of most selected genes. In addition, RT-PCR of 
a selected set of genes confirmed differential expression in the patient samples 
tested by microarray analyses and in four additional subjects. 
So far, there is only one study in which gene expression of different prostate 
zones was taken into account. Stamey et al. analyzed gene expression in the 
different prostate zones investigating which zonal tissue was most suitable as 
a control for differential gene expression analysis in prostate cancer (16). The 
gene expression profiles of PC were strongly affected by the zonal location of 
control tissue, which indicates the distinction between the normal prostate zones. 
Although it was not their purpose to investigate the genes that distinguish the 
normal peripheral from the normal transition zone, we still could extract zonal 
specific genes from their studies. We identified an overlap of 12 genes of the 18 
extracted genes between the two datasets (Table 3). This strongly supports the 
reliability of the data, considering that these independent studies were performed 
using two different microarray platforms and different patient samples. 
To exclude that the differential gene expression is due to a different cell type 
distribution, we quantified the amount of stromal and epithelial cells in frozen 
sections of both prostate zones. The average proportion of stromal and epithelial 
cells was 50:50 and this distribution was the same in both prostate zones. In 
addition, we performed RT-PCR analyses with markers for most common cell 
types and showed that there were no significant differences between the two 
zones. We speculate that the difference in gene expression is not caused by a 
difference in quantity of cells, but by a qualitative distinction in cell type charac-
teristics. Pathologists consider the morphology of the prostate zones alike and 
also Laczkó et al. (8) showed for several cell type markers that there were no 
significant differences between the peripheral and transition zone. An indication 
that qualitative cell type characteristics play an important role is the discovery 
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of 3 genes (ASPA, FLJ10970 and COCH), which were higher expressed in the 
transition zone and were also exclusively expressed in stromal cells. Also the 
comparison with the study from Stuart et al (15) indicates a contribution of cell 
type characteristics when it revealed a significant overlap between genes higher 
expressed in the transition zone and genes associated with stroma. The inter-
action between stroma and epithelium is crucial in the progression of prostate 
Table 3. Comparison of 346 differentially expressed genes from the prostate zones and the 
dataset from Stamey et al. (16). We could extract 40 genes from the dataset by Stamey et al. 
(Tables 3 and 4 (16)) that were differentially expressed between the normal prostate zones, of 
which 12 genes were higher expressed in the peripheral and 28 genes were higher expressed 
transition zone. 11 of the 28 genes from the transition zone were present on our oligoarrays, 
of which 9 were higher expressed in the transition zone in both datasets. 7 of the genes from 
the peripheral zone were present on our oligoarrays, of which 3 were higher expressed in the 
peripheral zone in both datasets. The table shows the 18 genes present on both arrays and 
the genes that overlap between the two studies. P, peripheral zone; T, transition zone.
cancer and BPH (9,11,17). Our data show that cell characteristics of stroma 
and epithelium and with that, the interactions between stroma and epithelium, 
may already be different in the two normal zones. Therefore, we could speculate 
GenBank_Acc Genes present on both arrays Log2 ratio P/T
Peripheral zone
NM_001935 DPP4 0.390481646
NM_000700 ANXA1 0.016763477
NM_004476 FOLH1 0.864793013
NM_004864 GDF15 1.709116833
NM_006475 POSTN 0.845773593
NM_005069 SIM2 fl agged
NM_000166 GJB1 fl agged
Transition zone
NM_003239 TGFB3 -1.257835567
NM_002899 RBP1 -1.07198958
NM_003304 TRPC1 -0.359069209
NM_006159 NELL2 -2.413583788
NM_001321 CSRP2 -0.511974608
NM_000049 ASPA -1.052217602
NM_006307 SRPX -0.978049822
NM_005278 GPM6B -0.748098383
NM_001928 DF -1.360622651
M62402 IGFBP6 -0.730010298
NM_001146 ANGPT1 fl agged
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that these zonal differences in stromal-epithelial interactions form the basis of 
susceptibility of the distinct prostate zonal diseases. 
There is a prominent overlap between the genes that were higher expressed 
in the normal peripheral zone and the genes that were reported to be higher 
expressed in PC (12-14). Dhanasekaran et al., Lapointe et al., and Singh et al. 
studied gene expression profiles of prostate confined PC as compared to gene 
expression in the normal prostate tissue. The comparison to our data revealed 
a set of genes that are higher expressed in normal peripheral tissue and PC in 
all datasets. Also the tumor-associated genes from the dataset from Stuart et 
al. overlapped with the genes higher expressed in the peripheral compared to 
transition zone. This significant overlap can be interpreted in two ways. First, the 
gene expression signature of the normal peripheral zone remains dominantly 
present in PC and simply displays its origin. Second however, the unique ex-
pression profile within the peripheral zone could demonstrate a zonal-specific 
microenvironment in which malignant rather than benign growth is supported. 
This implies that the genes that are up-regulated in prostate cancer are already 
highly expressed in the peripheral zone. In other words, this set of genes might 
be involved in origin and progression of PC. 
Two of the genes that were higher expressed in the peripheral zone were GDF15 
and TARP. Growth differentiation factor 15 (GDF15 also known as PLAB, PDF, 
MIC-1) is a growth factor and member of the bone morphogenetic protein family. 
Relatively little is known about the specific function of GDF15, but a number of 
factors link it to epithelial tumors. Liu et al (18) demonstrated that GDF15 se-
cretion was markedly increased in various PC cell lines and suggest a role for 
GDF15 in tumor dissemination. Also several others demonstrated that GDF15 
is higher expressed in PC than in normal tissue (19,20). Furthermore GDF15 
is strongly induced by p53 and it is up-regulated by androgens (21). TARP is 
another example of a gene that is higher expressed in the peripheral zone and 
PC. Like GDF15, TARP is up-regulated by androgens (22). Expression of TARP 
in PC3 cells resulted in a more rapid growth rate and differential gene expression 
in these prostate cancer cells (23). The higher expression of GDF15 and TARP 
in the normal peripheral zone and their potential role in PC, would support the 
hypothesis of the presence of a predisposing “cancer susceptibility signature” 
in the peripheral zone.
Since the malignant transformation of the transition zone is infrequent, the 
distinct expression profile within this zone might have a protective function with 
specific genes and pathways involved in anti-tumor processes. Two important 
development-regulating pathways of which several genes were found higher 
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expressed in the transition zone, include the Wnt and forkhead pathways. Wnt se-
creted proteins are essential mediators of cell-cell signaling during development 
and play a role in cell fate control and homeostasis. Importantly, deregulation of 
the Wnt pathway has been associated with cancer development and progres-
sion (24). Wissmann et al. (25) studied RNA expression levels of 40 genes of 
the Wnt pathway in primary prostate carcinomas and observed various genes 
to be up- and down-regulated in certain prostate cancers. These data further 
substantiated our notion of a complex role of tumor progression and tumor sup-
pression for the Wnt pathway, which is not yet fully comprehended. Wnt proteins 
and beta-catenin play a role as mediators of epithelial-mesenchymal interactions 
in various organs. We observed higher expression of several genes of the Wnt 
pathway in the transition zone of the prostate and hypothesize that this pathway 
might contribute, via stromal-epithelial interactions, to the distinction of the be-
nign and malignant disease development in the transition and peripheral zone. 
Next to the Wnt pathway, we observed that several members of the forkhead 
gene family were higher expressed in the transition zone. The forkhead genes 
encode a family of transcription factors, which are regulators of development. 
During embryogenesis, many tissues and cell populations express particular 
forkhead proteins (26). Forkhead family member FOXO3a can induce a delay 
in the G2-M phase of the cell cycle, in response to stress stimuli during which 
FOXO3a contributes to repair of damaged DNA. It was also hypothesized that 
under high levels of stress it might induce a program of cell death (27). Alvarez 
et al. (28) demonstrated that forkhead transcription factors have a function in 
the control of mitotic gene expression, conserved from yeast to mammals. Both 
studies and more, indicate a protective role of the forkhead genes in the process 
of oncogenic transformation. Interestingly, two of the forkhead genes that were 
higher expressed in the transition zone, FOXF1 and FOXF2, were also higher 
expressed in mesenchyme compared to epithelium during embryogenesis, and 
may have functions in epithelial-mesenchymal cross-talk (29). The identifica-
tion of zonal-specific expression of genes of the Wnt and forkhead pathways, 
strengthens our concept that stromal-epithelial interactions are important in the 
dissimilarity of the prostate zones. In addition, both these pathways may con-
tribute to the development of benign disease and protection against frequent 
malignant transformation of the transition zone of the prostate.
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Abstract
Objective. Since the first forkhead transcription factor (Fox) was identified, its 
family members have been implicated in a variety of cellular processes including 
embryonic development and disease. Here, we focus on the unexplored expres-
sion of forkhead transcription factors in normal prostate and prostate diseases. 
Material and Methods. We analyzed a set of 12 different forkhead transcription 
factors by quantitative RT-PCR in the prostate zones, prostate cancer, lymph 
node metastases, benign prostatic hyperplasia (BPH), xenografts and several 
prostate cell lines.
Results. Striking differences between the expression of various forkhead family 
members were observed. Most prominent were the high expression of FOXF1 
and FOXF2 in the normal prostate transition zone and BPH and their decreased 
expression in prostate cancer. Interestingly, although the FOXF genes are stroma-
specific, some of the androgen-independent prostate cancer xenografts uniquely 
express these two genes. FOXD1 and FOXD2 were higher expressed in prostate 
cancer and lymph node metastases. FOXA1 and FOXC1 have an opposite ex-
pression pattern with respect to androgen-dependent growth of prostate cancer 
cell lines and xenografts. 
Conclusions. Various members of the Fox family are differentially expressed in 
the zones of the normal prostate and in benign and malignant outgrowths. The 
expression profiles of FOXF1 and FOXF2 genes suggest a role in epithelial to 
mesenchymal transition (EMT), while FOXA1 and FOXC1 expression is linked 
to androgen-associated growth status of cancer.
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Introduction
It has been more than a decade since discovery of the Drosophila transcription 
factor forkhead and subsequent identification of the mammalian orthologues 
of the forkhead DNA binding domain (1). Forkhead genes encode a subgroup 
of helix-turn-helix class of proteins. The arrangement of loops connecting the 
β strands that flank one of the three α helices, gives rise to a butterfly like ap-
pearance, hence the name “winged-helix” transcription factors (2). It is a relatively 
invariant structure, with most amino acids being conserved between family 
members. This has made it difficult to understand the molecular mechanisms 
underlying the sequence specificity of the DNA-binding domains. All forkhead 
factors can bind DNA and the functional effect of this can be either the activation 
or the inhibition of gene transcription. In contrast to the DNA-binding domains, 
there is almost no sequence homology between the transactivation or repres-
sion domains of members of the forkhead family, and little is known about their 
interactions with the transcriptional machinery (3). The forkhead family has been 
implicated in a variety of cellular processes and they play an important role in 
embryonic development and disease. Several forkhead factors, like FOXP3, 
FOXN1, FOXJ1 and members of the FOXO subfamily have crucial roles in 
various aspects of the immune system (4,5). Lehmann et al. (6) suggested the 
importance of forkhead factors in disease and development and speculated that 
soon regulators and downstream target genes of forkhead transcription factors 
will be discovered to explain a range of human diseases. 
Little is known about the role of the forkhead family in the developing and adult 
prostate. Immunohistochemical localization of Foxa1 and Foxa2 revealed epi-
thelial nuclear staining of both members in the developing mouse prostate, but 
only Foxa1 in the adult mouse prostate (7,8). Foxa1 is essential for full prostate 
ductal morphogenesis as was demonstrated using Foxa1-deficient mice (8). 
During prostate cancer progression, FOXA1 remains highly expressed in the 
cancer epithelium, while FOXA2 is turned on in neuroendocrine small cell-type 
carcinomas (9). A direct link between prostate cancer progression and Foxm1 
was established by the observation that transgenic Foxm1 mice, crossbred with 
the TRAMP and LADY prostate cancer mouse models, had accelerated develop-
ment and growth of prostatic tumors (10).  
The role of various Fox genes in prostate cancer progression might be explained 
by their interaction with the androgen receptor (AR) pathway. The AR is a nuclear 
receptor that is activated upon testosterone or dihydrotestosterone binding and 
generally signals growth of prostate cancer cells (11). Besides the above men-
tioned FOXA1 and FOXA2, also FOXG1, FOXH1, FOXO1 and FOXO3 affect the 
AR cascade. The general theme is that these Fox proteins (all except FOXO3) 
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repress AR activity by directly binding the AR protein. Takayama et al. support 
this idea and show that FOXP1 is an androgen-responsive transcription factor 
that negatively regulates AR signaling in prostate cancer cells (12).  
In our previous study, it was found that forkhead transcription factors are dif-
ferentially expressed between the prostate zones (13). FOXF1 and FOXF2 are 
higher expressed in the transition zone as compared to the peripheral zone. This 
observation initiated our interest in the potential role of Fox genes in prostate 
disease development since benign prostatic hyperplasia (BPH) and prostate 
cancer preferentially occur in the transition and peripheral zone, respectively. In 
order to identify which forkhead genes are expressed in the prostate and relate 
their expression to prostate diseases and cell types, we investigated expression 
of 12 different forkhead transcription factors by real time RT-PCR. 
Materials & Methods
Samples and cell lines
The prostate specimens were obtained from patients who underwent a radical 
prostatectomy at the Department of Urology, Erasmus MC. The experimental pro-
tocols were approved by the Erasmus MC Medical Ethics Committee according 
to the Medical Research Involving Human Subjects Act. Prostate samples include 
normal tissue from the transition and peripheral zones and benign prostatic 
hyperplasia (BPH) from a special protocol described previously (13). Prostate 
cancer samples from the prostate and from lymph node metastases (Table. 1) 
were obtained from the frozen tissue bank of the Erasmus Medical Center as de-
scribed by Hendriksen et al. (14). The prostate samples used by different groups 
(15-19) in Figure 1 were all macrodissected. Macrodissection generally implies 
that immediately after surgery the pathologist macroscopically isolates different 
prostate samples. Presence and amount of cancer cells and other cell types are 
then evaluated using histology. One of the issues that need to be considered 
is that it is impossible to macrodissect prostate cancer samples without normal 
epithelium or stroma contaminating the sample. You would need to microdissect 
the samples to enrich for cancer tissue and separate cancer cells from normal 
epithelium and the stromal compartment.
However, since the stroma has been indicated to play a major role in cancer 
initiation and progression, it is of great importance to study prostate cancer 
cells in context with their surrounding stroma. In most gene expression studies 
including our own, macrodissected prostate cancer tissue was used to examine 
expression profiles of the whole tumor tissue including cancer cells and their
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Table 1. Clinical characterization and follow up of patients
 
normal prostate organ-confined 
prostate cancer,
no metastases
organ-confined 
prostate cancer, 
developed me-
tastases
No. patients, unique 17 36 10
age at treatment, median (range) 61 (54-72) 61.5 (49-73) 64 (49-70)
Gleason score, n    
6  23 4
7  9 2
8-10  2 4
PSA at diagnosis (ng/ml) median (range)  9.2 (0.3-181) 32 (0.5-64.3)
epithelium in tissue (average %) (range) 68 (60-80) 80 (60-100) 81 (70-90)
cancer in tissue (average %) (range) 0 85 (70-100) 90 (70-100)
supporting environment such as fibroblasts, smooth muscle cells, endothelium, 
and more. In this study we demonstrate that the stroma-specific genes FOXF2 
and FOXF1 are implicated in human prostate disease and if these samples 
were cancer-cell enriched by microdissection, we would not have found this 
association. It is essential to realize that if one wants to study gene expression 
changes in cancer development, to take all different cell types present in the 
tumor into consideration. Types of arrays used by different groups: Singh et al. 
(15) and Stuart et al. (16) used Affymetrix U95Av2 arrays for their experiments, 
Lapointe et al. (17) used cDNA array containing 26260 probes, Varambally et al. 
(18) used Affymetrix U133 2.0 arrays and Yu et al. used Affymetrix HG_U95A,B,C 
(19). Primary human prostate epithelial cells (PrEC) and primary human prostate 
stromal cells (PrSC) were purchased and cultured according to manufacturer’s 
guidelines (Clonetics Human and Animal Cell Systems, Cambrex Bio Science 
Walkersvill, Inc., USA). To minimize adaptation and variation of cells, only early 
passages 5 and 7 were used for RNA isolation when they were 70% confluent.
The LNCaP, PC3 and DU145 prostate cancer cell line was maintained in RPMI 1640 
with 5% FCS and penicillin/streptomycin (Invitrogen, Merelbeke, Belgium). Before 
R1881 treatment, LNCaP cells were androgen deprived for 72 hours in medium 
containing 5% dextran-filtered, charcoal-stripped FCS with a medium replacement 
after 36 hours. After androgen deprivation, the medium was supplemented for 2, 
4, 6, or 8 hours with 1 nmol/L R1881 or ethanol vehicle. The basic culture medium 
used in the maintenance of PC346 cell lines consisted of DMEM-F12 (Cambrex 
BioWhittaker, Verviers, Belgium) supplemented with 2% FCS (PAN Biotech, Aiden-
bach, Germany), 1% insulin-transferrin-selenium (GIBCO BRL, Gaithersburg, MD), 
0.01% BSA (Boehringer-Mannheim, Mannheim, Germany), 10 ng/ml epidermal 
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growth factor (Sigma-Aldrich, Milan, Italy) and penicillin/streptomycin antibiotics 
(100 U/ml penicillin, 100 g/ml streptomycin; Cambrex BioWhittaker) plus the 
following additions: 100 ng/ml fibronectin (Harbor Bio-Products, Tebu-bio, the 
Netherlands), 20 g/ml fetuine (ICN Biomedicals, Zoetermeer, The Netherlands), 
50 ng/ml cholera toxin, 0.1 mM phosphoethanolamine, 0.6 ng/ml triiodothyronine 
and 500 ng/ml dexamethasone (all from Sigma-Aldrich).
The in vivo growing xenografts PC82, PC133, PC135, PC295, PC310, PC324, 
PC329, PC339, PC346, PC346I, PC346B, PC346BI, PC374 and PC374F were 
propagated by serial transplantation on male nude mice as described (20,21). 
PC82, PC295, PC310, and PC329, derived from primary tumors or local me-
tastases, are androgen-dependent. PC133, PC324, PC339, PC346, PC346I, 
PC346B, PC346BI, PC374 and PC374F are derived from distant metastases 
or local progressive disease and are androgen-independent (PC133, PC324 
and PC339) or androgen-sensitive (PC346 and PC374). PC135 is androgen 
independent and is derived from a lymph node metastasis.
RNA isolation and quantitative real-time Reverse Transcription Polymerase 
Chain Reaction (RT-PCR)
RNA from prostate specimens and cell lines was isolated using RNAbee reagent 
as described by the manufacturer (Tel-Test, Inc. Friendswood, TX, USA). The 
reverse transciptase reaction was performed with 1 µg RNA from the samples 
with oligo-T12 primer and pre-incubated for 10 minutes at 70°C. First Strand 
buffer, DTT, dNTPs and RNAsin were added and incubated for 2 minutes at 
37°C. The RT reaction was initiated by MMLV-RT and incubated for 1 hour at 
37°C. After this, the reaction was kept 10 minutes at 90°C and immediately 
thereafter frozen.
Quantitative real-time RT-PCR analysis was done with an ABI Prism 7700 Se-
quence Detection System using AmpliTaq Gold according to the manufacturer’s 
specifications (Applied Biosystems, Foster City, CA). The probes and primers for 
Taqman Gene Expression Assays were purchased by Applied Biosystems. The 
amount of target gene expressed was normalized to an endogenous reference 
and relative to a calibrator. The endogenous reference was glyceraldehyde-
3-phosphate dehydrogenase; a mixture of cDNAs of the prostate carcinoma 
xenografts was used as the calibrator. The following primers were used: FOXA1, 
Hs00270129_m1; FOXC1, Hs00559473_s1; FOXJ2, Hs00218236_m1; FOXK2, 
Hs00189612_m1; FOXN1, Hs00186096_m1; FOXM1, Hs00153543_m1; FOXF1, 
Hs00230962_m1; FOXF2, Hs00230963_m1; FOXP1, Hs00415004_m1; FOXD1, 
Hs00270117_s1; FOXD2, Hs00270129_s1; GAPDH, Hs99999905_m1.
Statistical analysis for comparison of the RT-PCR data was performed using a 
paired t-test.  
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Results
Twelve different forkhead transcription factors (Fox) were analyzed by quantita-
tive RT-PCR analyses in prostate cancer cell lines, xenografts, normal prostate 
tissues, BPH and prostate cancer tissue. Fox genes were selected based on 
differential gene expression in various microarray studies and published literature 
mentioned above with respect to cancer and AR interaction (Figure 1) (15-19). 
Figure 1. In silico expression analysis of several Forkhead transcription factors in microar-
ray databases related to normal prostate and prostate diseases. Difference in expression in 
prostate cancer (PC) and metastasized prostate cancer (Met-PC) as compared to normal 
prostate tissue was based on microarray studies by Singh et al. (15) column 2, Lapointe et 
al., (17) columns 3 and 7, Varambally et al. (18) columns 4 and 8, Yu et al. (19) columns 5 and 
9. Columns 1 and 6 are averages of these studies of PC versus normal and Met-PC versus 
normal, respectively. Expression ratios between PC versus normal prostate (NP) and MET-PC 
versus NP are shown in different intensity colours. Gene expression was ordered by Excel 
sorting from highest to lowest expression and illustrated by Treeview. Red indicates higher 
expression in PC or MET-PC as compared to NP. Green indicates the opposite. Stroma and 
tumor-associated expression of Fox genes are represented by columns 10 and 11 and based 
on a study by Stuart et al. (16). Red indicates a significant positive correlation and green a 
significant negative correlation between gene expression and amount of stroma or tumor. 
Fox gene expression in prostate cancer cell lines and xenografts
The expression of the 12 Fox genes was investigated in different prostate cancer 
cell lines including the androgen receptor positive LNCaP and PC346C, and the 
androgen-independent PC3 and DU145 (Figure 2a). In addition, expression was 
determined in our panel of prostate cancer xenografts, consisting of androgen-
dependent, sensitive and independent growing tumors (22,23). Since the pros- 
tate cancer xenografts contain mouse contaminants such as stroma, endothe-
FOXM1
1 2 3
PC
versus NP
MET-PC
versus NP st
ro
m
a-
as
so
ci
at
ed
tu
m
or
-a
ss
oc
ia
te
d
4 5 6 7 8 9 10 11
FOXD1
FOXD2
FOXH1
FOXK2
FOXP1
FOXN1
FOXA1
FOXJ2
FOXF2
FOXC1
FOXF1
Chapter 3
48
lium and blood cells, each quantitative RT-PCR Fox gene assay was checked 
for cross-reactivity with RNA extracted from mouse sarcoma tissue. None of 
the RT-PCRs gave detectable signals on mouse tissues within the first 35 PCR 
cycles, showing human-specific gene expression detection (data not shown).   
In Figure 2a, the strict androgen-dependent PC82, PC295, PC310 and PC329 
were compared to the AR negative PC133, PC135, PC324 and PC339. Some of 
the Fox genes have a xenograft or cell line-specific expression pattern, explaining 
the outsized error bars. FOXC1 is notably expressed in all androgen-independent 
xenografts, but extremely high in PC135. Also FOXN1 is mostly undetectable, 
except for high expression in DU145 and PC135. FOXP1 is a unique outlier 
with high expression in PC295 (more information on individual cell lines and 
xenografts in supplementary Table 1).
One of the most striking observations in the comparison between androgen-
dependence and independence is the inverse expression pattern of FOXA1 
and FOXC1. While FOXA1 is higher expressed in androgen-dependent cell 
lines and xenografts, FOXC1 reveals an opposite association (Figure 2b). Also 
expression of FOXF1 and FOXF2 stands out by the unique expression in some 
androgen-independent xenografts (Figure 2c).
Whether any of the Fox genes is directly androgen regulated was determined 
by gene expression analysis of LNCaP cells cultured for 8 hours in the absence 
or presence of 1 nM R1881. None of the 12 Fox genes showed a significant 
difference upon androgen treatment, which is in agreement with published ex-
pression microarray data that so far, did not identify Fox genes as potential AR 
targets in LNCaP cells (24). In contrast, Takayama et al. recently published that 
FOXP1 is an androgen-responsive transcription factor that negatively regulates 
AR signaling in prostate cancer cells (12).  
Fox gene expression in primary prostate epithelial and stromal cells
Primary human prostate stromal cells (PrSC) and primary human prostate epithe-
lial cells (PrEC) were used to study the expression of Fox genes in normal pros-
tate stroma and epithelium (Figure 3). FOXF1 and FOXF2 were highly expressed
in PrSC, but not in PrEC, which confirms previous findings that these genes are 
highly stroma-specific (25). FOXH1, FOXA1 and FOXP1 were not expressed, 
while the other Fox genes tested, show low expression with no or minor differ-
ences between PrSC and PrEC.
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Figure 2. a) Expression analysis of Fox genes in various prostate cancer androgen-dependent 
(AD cells) and independent (AI cells) cell lines and xenografts (AD xenos and AI xenos).  Ex-
pression of Fox genes was investigated by quantitative RT-PCR analyses of RNA extracted 
from androgen-dependent cell lines (LNCaP and PC346c), androgen-independent cell lines 
(DU145 and PC3), androgen-dependent xenografts (PC82, PC295, PC310 and PC329) and 
androgen-independent xenografts (PC133, PC135, PC324 and PC339). Data are represented 
as averaged ratio of Fox gene expression/GAPDH expression (±SEM).
b) Gene expression analyses of FOXA1 and FOXC1 in human prostate cancer xenografts; 
androgen-dependent, AR positive (AR+); androgen-responsive, AR+; androgen-independent, 
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AR+ and androgen-independent, AR negative (AR-). Expression is represented as ratio of 
FOXA1 or FOXC1 gene expression/GAPDH expression. c) Gene expression analyses of 
FOXF1 and FOXF2 by quantitative RT-PCR in several types of human prostate cancer xeno-
grafts. Expression is represented as ratio of FOXF gene expression/GAPDH expression.
Figure 3. Gene expression analyses of several Fox genes in human prostate primary stromal 
(PrSC) and epithelial cells (PrEC). Expression is represented as ratio of Fox gene expression 
/GAPDH expression.
Fox gene expression in normal prostate and prostatic diseases 
In order to identify differential expression of the selected Fox genes between 
the normal prostate, benign prostatic hyperplasia (BPH) and prostate cancer 
(PC), RNA was extracted from the normal prostate transition zone (TZ) and 
peripheral zone (PZ) of 7 radical prostatectomy samples and from 5 samples 
of BPH, 10 samples of organ-confined PC and 6 PC lymph node metastases 
(LN) (Figure 4). 
Expression of FOXH1 and FOXM1 was in all cases very low and not significantly 
different between the various groups (data not shown).
The quantitative RT-PCR confirmed our previous finding that FOXF1 and FOXF2 
are higher expressed in the TZ as compared to the PZ (12). FOXA1, FOXC1, 
FOXJ2 and FOXK2 were equally expressed between the prostate zones. FOXP1 
was higher expressed in PZ, while FOXD1 and FOXD2 were expressed at a very 
low level in the normal prostate.
With respect to prostate diseases, most Fox genes are somewhat higher ex-
pressed in BPH as compared to the expression in normal TZ in which the benign 
enlargement originates (FOXC1, FOXP1, FOXJ2 and FOXK2) (Figure 4). Both 
FOXF1 and FOXF2 remain highly expressed in BPH but not different from TZ. The 
PC malignant growths, revealed a more differential pattern. FOXD1 and FOXD2
are up-regulated in PC and LN as compared to gene expression in the normal 
PZ. On the other hand, FOXF1 and FOXF2 show a consistent down regulation 
upon progression of the malignant disease.
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Figure 4. Gene expression of several Fox genes in prostate cancer (PC), benign prostatic hy-
perplasia (BPH), lymph node metastasis (LN), peripheral zone (PZ) and transition zone (TZ).
Predictive value of Fox gene expression in radical prostatectomy samples
Since the expression pattern of FOXF1 and FOXF2 in PZ, PC and LN are op-
posite from FOXD1, we investigated if any of these genes or their combination 
could predict whether local cancer after radical surgery recurs (Figure 5). FOXF1 
and FOXF2 were significantly higher expressed in normal prostate (n=17) as 
compared to local prostate cancer (n=46) confirming the data shown in Figure 
4. Also the higher expression of FOXD1 in PC as compared to normal prostate 
was substantiated. However, there was no expression difference of these three 
Fox genes between men that did (n=10) or did not (n=36) develop metastases 
after radical prostatectomy.
Figure 5. Expression comparison of FOXF1, FOXF2, FOXD1 in normal prostate (NP) and 
organ-confined prostate cancer in patients that did (PC+MET) or did not (PC-MET) develop 
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metastases after radical prostatectomy. FOXF1 and FOXF2 are significantly higher expressed 
in NP compared to PC+/-MET. FOXD1 is highest expressed in PC+MET compared to NP and 
is also higher expressed in PC-MET compared to NP. In each comparison NP is significantly 
different from PC + and – MET (P<0.05).  
 
Discussion
The aim of this study was to get a better understanding of the expression and 
potential roles of forkhead transcription factors in the healthy and diseased pros-
tate. Although the importance of Fox genes in development and disease is well 
established, their potential role in prostate development and outgrowths is poorly 
studied (4,5,26). Twelve different Fox genes were selected and gene expression 
was studied by quantitative RT-PCR analyses in various prostate tissues.
Several of the selected Fox genes have a clear differential expression pattern in 
the comparisons presented. FOXF1 and FOXF2 were selected based on their 
association to stroma, lower expression in prostate cancer (Figure 1) and their 
significant higher expression in TZ as compared to PZ and (13). We confirmed 
that expression is decreased in prostate cancer andprostate cancer metastases 
and showed that FOXF expression is stroma-specific. Taken together, it appears 
that FOXF1 and FOXF2 are involved in regulating normal prostate homeostasis 
through the stromal compartment, particularly in the TZ. This role for FOXF genes 
was already suggested for mice in murine gut development and during mouse 
and rat embryogenesis (27). Like for mouse gut development, we suggest that 
these genes are involved in stromal-epithelial interaction. Importantly, the FOXF 
genes might also play a role in epithelial-mesenchymal transition (EMT) since 
the stroma-specific FOXF genes are expressed uniquely in several late stage 
androgen-independent xenografts. 
FOXD1 is higher expressed in prostate cancer and lymph node metastases as 
compared to normal prostate. We investigated whether this opposite expres-
sion pattern of FOXF1/FOXF2 and FOXD1 would be different between primary 
tumors that will or will not form metastatic disease after radical prostatectomy 
with intention to cure. A more extensive quantitative RT-PCR analysis clarified 
that their expression had no prognostic value. 
It is suggested that FOXA proteins play a role in development and progression of 
prostatic adenocarcinoma (9). Average FOXA1 expression was higher in peripheral 
zone, prostate cancer and lymph node metastases as compared to BPH and 
transition zone. Due to considerable variability between the patient samples, 
this difference did not reach statistical significance. We observed an inverse 
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expression pattern of FOXA1 and FOXC1 between androgen-dependence and 
independence. FOXA1 is higher expressed in AR positive, androgen-dependent 
cell lines and xenografts, while FOXC1 reveals an opposite expression pattern. 
We extracted data from Bild et al. (28) and identified the same inverse expres-
sion pattern of FOXA1 and FOXC1 in estrogen receptor positive versus negative 
breast cancer cell lines (supplementary Figure 1). In agreement, FOXA1 was 
shown to be a prognostic marker for luminal subtype breast cancers by Thorat 
et al. (29). Also our data indicates a potential role for FOXA1 and FOXC1 as 
markers for androgen-dependent growth of prostate cancer.
Supplementary figure 1. Expression of estrogen receptor alpha (ESR1), FOXA1 and FOXC1 
in breast cancer cell lines. Affymetrix gene expression data was retrieved from Bild et al (28) 
and it was normalized and mean centered for each of the genes. Cell lines were ordered from 
highest to lowest ESR1 expression. FOXA1 is always high expressed in ESR1 positive cell 
lines and poorly expressed in ESR1 negative cells. FOXC1 reveals an opposite expression 
pattern. As shown in Figure 2b, this expression pattern is highly similar to the expression 
correlation of the AR and FOXA1/FOXC1 in prostate cancer xenografts.
This inventory of the expression of 12 Fox genes in several prostate tissues further 
provided evidence for a role of forkhead transcription factors in prostate main-
tenance and abnormal outgrowths. FOXF genes and FOXD1 are differentially 
expressed between normal and cancer, while FOXA1 and FOXC1 expression 
changes during PC progression, indicating their involvement in regulating the 
balance between normal and diseased tissue. 
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Abstract
Background. FOXF2 is a member of the large family of forkhead transcription 
factors and its expression pattern suggests a role in prostate cancer develop-
ment. FOXF2 expression is stroma-specific and higher expressed in the prostate 
transition zone than the prostate peripheral zone. Moreover, expression of FOXF2 
is decreased in prostate cancer.
Methods. To identify the genes and pathways regulated by FOXF2, we compared 
microarray expression profiles of primary prostate stroma cells (PrSC) treated 
with control or siRNA directed against FOXF2.  
Results. From our microarray analyses, we selected 190 differentially expressed 
genes, of which 104 genes were higher expressed in PrSC cells treated with 
FOXF2 siRNA and 86 were higher expressed in PRSC cells treated with nega-
tive control siRNA. Eight of the strongest differentially expressed genes were 
validated by RT-PCR. Genes down-regulated by FOXF2 included MT1E, MT1F, 
PDGFA, ITGB1 and PSG7 and genes up-regulated by FOXF2 included WASF2, 
BAMBI and CXCL12. Ingenuity pathway analysis showed several pathways sig-
nificantly regulated by FOXF2, including PPAR signaling, PDGF signaling and 
ECM signaling. GSEA analysis revealed that FOXF2 up-regulated genes were 
down-regulated in the same PrSC cells treated with TGFβ3.
Conclusions. The distinct expression pattern of FOXF2 in the prostate, its 
effect on expression of extracellular matrix signaling, and its opposing role in 
the TGFβ3 pathway, suggests a role for FOXF2 in prostate homeostasis and 
stroma-epithelial interactions. 
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Abstract
Foxf2 knockout mice give rise to a gene specific phenotype in which the embryos 
develop to term and die within hours after birth due to a cleft in the secondary 
palate preventing proper feeding and breathing. After exploring FOXF2 gene 
expression and FOXF2 regulated pathways in human adult prostate in previous 
studies, the potential role of Foxf2 in prostate development was investigated. To 
accomplish this, histology of the urogenital sinus (UGS) of wild-type mice and 
Foxf2 knockout mice was compared. Overall, no significant differences in origin 
of UGS, like urethra and prostatic bud formation, were observed. However, at 
cellular level considerable differences were observed between the wild-type mice 
and Foxf2 knockouts. The stromal compartment in Foxf2 knockouts showed less 
extracellular eosinofilic matrix, which indicates a role for FOXF2 in attachment 
of proteins to the cell-matrix. Furthermore, the extracellular matrix seemed 
disordered and also the epithelial cells of the prostate ducts appeared less well 
organized. These findings are in concurrence with our recent microarray data 
on human prostate target genes of FOXF2, in which we established that various 
extracellular matrix (ECM) proteins are regulated by FOXF2. The data are also 
in agreement with the abnormal gut phenotype, in which extracellular matrix, 
particularly collagens, were severely reduced in Foxf2 mutant intestine, which 
caused epithelial depolarization and tissue disintegration. Apparently, Foxf2 is not 
involved in prostate formation, but might control stromal-epithelial interactions.
Introduction
Evidence accumulates that carcinogenesis often involves deregulation of path-
ways that are important in development (1). Understanding how the mammalian 
prostate develops and functions will contribute to a better understanding of 
prostate cancer. In human prostate, differential gene expression was discovered 
between the prostate zones, which indicates, that predestination of prostate 
diseases originates in the prostate zones (2). FOXF2 was highly expressed in 
the transition zone of the prostate, stroma specific and it was higher expressed 
in normal prostate compared to prostate cancer. FOXF2 was also considered to 
be involved in epithelial to mesenchymal transition since it was highly expressed 
in androgen-independent xenografts (3). These findings suggest an important 
role for FOXF2 in stroma-epithelial cross-talk. After exploring FOXF2 gene ex-
pression and FOXF2 regulated pathways in human adult prostate in previous 
studies, we wanted to identify the potential role for Foxf2 in prostate develop-
ment. An important tool to study the effect of loss of a gene of interest in organ 
development is the knockout mouse model. We made use of Foxf2 knockout 
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mice, which give rise to a gene specific phenotype, in which the Foxf2 mutants 
develop to term and die within hours after birth due to a cleft in the secondary 
palate preventing proper feeding and breathing (4). Furthermore, Foxf2 mutants 
suffer from gastrointestional defects. Extracellular matrix, especially collagens, 
was severely reduced in Foxf-/- intestine, which caused epithelial depolariza-
tion and tissue disintegration. Ormestad et al. concluded that Foxf proteins 
are mesenchymal factors that control epithelial proliferation and survival and 
link hedgehog to Bmp and Wnt signaling (5). Aitola et al. suggested that Foxf2 
is expressed in mesenchyme of tissues where stromal-epithelial interaction is 
needed for morphogenesis and cell differentiation (6). Foxf2 is highly expressed 
in urinary tract and is expressed adjacent to the transitional epithelium (7). The 
prostatic buds begin to appear from urogenital epithelium at approximately E17 
and develop and branch within the urogenital mesenchyme (8). We studied the 
urogenital sinus (UGS) of E18.5 embryos of Foxf2-/- and wild-type mice, in par-
ticular the prostatic ducts and neighboring mesenchyme. To investigate whether 
changes in expression of Foxf2 in prostate development is associated with 
FOXF2 regulated genes in men; we performed immunohistochemical staining 
of metallothioneins and laminins.
Material & Methods
Immunohistochemistry
Wild-type and Foxf2-/-  E18.5 embryos were obtained from Dr. P. Carlsson, Lund-
berg lab, Gothenburg, Sweden and stored in formalin (4). Tissues for immunohis-
tochemistry were fixed in freshly prepared buffered 4% formalin for approximately 
16 h at room temperature, dehydrated and embedded in paraffin. The UGS was 
isolated from the mouse embryo before paraffin sections were made. Sections 
were cut at 4 µm and attached to AAS-coated slides. Antibodies used for im-
munostaining were directed against Laminin (M0638, DAKO), Metalothionein 
(M0639, DAKO).  Microwave treatment for antigen unmasking was applied by 
boiling in 10 mM sodium citrate (pH 6.0) for 15 minutes and cooling at room 
temperature for 30 minutes. Primary antibodies were incubated overnight at 
4°C, and incubation with biotin labeled secondary antibodies was performed 
for 1 h at room temperature (Goat Anti-Mouse-biotin (E0433, 1:400, DAKO) or 
Rabbit Anti-Goat biotin (SC-2774, 1:400, Santa Cruz). Immunoreactivity was 
visualized by streptavidin-peroxidase incubation (HK320-UK, 1:50, BioGenex, 
San Ramon, CA).
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Results
Histological analysis of the UGS in Foxf2 knockout and wild-type mice
The UGS was investigated in Foxf2 knockout mice to study the phenotypic 
changes. H&E stained paraffin sections of 5 different 18,5E embryos were mi-
croscopically analyzed in wild-type mice versus Foxf2 mutants.  Prostatic buds 
arise from the urethra and are surrounded by stroma. Phenotypic differences were 
found between the Foxf2-/- and wild-type mice (Figure 1). The stroma compart-
ment in Foxf2 knockouts show less extracellular eosinofilic matrix. The stroma 
appears chaotic and gaps between the cells dominate the area (a). Cells sur-
rounding the epithelial ducts detached in several Foxf2 mutants (b) and several 
parts of the epithelial compartment, like the prostate ducts (c), appeared less 
organized than in wild-type mice. 
Laminin expression in the UGS of wild-type and Foxf2-/- mice
Laminin consists of a large family of proteins which are components of extracel-
lular matrix. The main non-collagenous component of the basal lamina is laminin, 
which forms the sheets of protein that form the substrate for of all internal organs. 
Laminin proteins are important because they form sheets that holds overall 
body structures together (9). Previously, it was observed that FOXF2 regulates 
expression of several ECM proteins, including lama1 and lamc2, which were 
down-regulated by FOXF2. For this reason laminin was analyzed by immuno-
histochemistry in the UGS. We observed that knockdown of Foxf2 resulted in 
distorted ECM. Laminin appears to be higher expressed in the cytoplasm of the 
stromal compartment of Foxf2-/- mice compared to wild-type mice (Figure 2).
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Figure 1. Phenotypic differences of the urogenital sinus in Foxf2 mutant compared to wild-
type mice. Arrows indicate: a stroma, b cell layer around epithelial prostate ducts, c prostate 
ducts, d seminal vesicles, e urethra. Left 100x and right 400x magnification. 
Figure 2. Laminin expression in Foxf2 mutant and wild-type mice. Expression of laminin in 
the stromal compartment around the prostatic ducts is higher in Foxf2-/- mice compared to 
wild-type mice.  Magnification 200x
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Metallothionein expression in the UGS of wild-type and Foxf2-/- mice
Metallothioneins (MTs) have been reported to be differentially expressed in 
tumors and a specific role for MTs in prostate oncogenesis was suggested by 
Moussa et al (10,11). Within the metallothionein gene locus on chromosome 
16 MT1E, MT2a, MT1F, MT1G, MT1H, MT1X were down-regulated by FOXF2 
in human prostate stromal cells (chapter 3). To investigate their protein expres-
sion in prostate histology, we analyzed metallothionein in 2 different Foxf2-/- and 
wild-type mice. Metallothioneins are higher expressed in the prostate ducts, as 
compared to the surrounding mesenchyme, of Foxf2-/- mutants compared to 
wild-type mice (Figure 3). This is in concordance with the previous findings in 
adult prostate.
Figure 3. Metallothionein expression in Foxf2 mutant and wild-type mice. Expression of 
metallothionein in the prostatic ducts is higher in Foxf2-/- mice compared to wild-type mice. 
Magnification 200x
Discussion
The aim of this study was to get a better understanding of the role of forkhead 
transcription factor Foxf2 in prostate development. In our previous work we have 
shown that FOXF2 is higher expressed in the transition zone compared to the 
peripheral zone of the adult prostate and that it is mainly expressed in prostate 
stroma (2). In addition, FOXF2 expression was decreased in prostate cancer 
compared to normal prostate (3). Its high expression in androgen independent 
xenografts suggested a role in epithelial tot mesenchymal transition. Altogether, 
it appears that FOXF2 is involved in regulating normal prostate homeostasis 
through the stromal compartment, particularly in the transition zone. This role for 
Foxf genes was already suggested in murine gut development and in mouse and 
rat embryogenesis (5,7). In order to identify a potential role for Foxf2 in prostate 
development, we investigated the UGS of   Foxf2-/- and wild-type mice. H&E stained 
Wild-type Foxf2-/-
Aberrant urogenital sinus histology in Foxf2 knockout mice
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paraffin sections of wild-type mice versus Foxf2 mutants were microscopically 
analyzed and important differences between the wild-type mice and Foxf2 mu-
tants were observed. Less extracellular eosinofilic matrix was observed in the 
stromal compartment of Foxf2 knockouts. The stroma appears chaotic and there 
were more gaps between the cells than in wild-type mice. The epithelial cells of 
the ducts appeared disorganized. Foxf2 seems to modulate cell-matrix attach-
ment and formation of adhesion structures. Furthermore, protein expression of 
metallothioneins and laminins was analyzed and we showed higher expression 
of both proteins in Foxf2 mutants compared to wild-type mice. Ormestad et 
al. investigated the role of Foxf2 in gut development and found pour adhesion 
between cells, in which epithelial, mesenchyme and two muscular layers were 
separated from each other. The basal lamina and basement membrane were 
both indistinct and frequently replaced by gaps of extracellular space and ECM 
staining was reduced. In fibroblast cell studies it was shown that inhibition of 
Foxf target genes lead to loss of collagen synthesis and suggested a role for 
Foxf proteins in ECM production by fibroblasts (7). This is in concurrence with 
our data and so it is probable that also in prostate development Foxf2 plays a 
similarly important role in ECM modeling. 
In the future, creation of conditional Foxf2 knockouts in various adult mouse 
models would be very informative to further elucidate the function of Foxf2. In 
conclusion, the current findings in UGS are in concurrence with the data of our 
recent microarray studies were we investigated human target genes of FOXF2 
in the prostate, in which we established that ECM proteins are regulated by 
FOXF2. 
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Origin of prostate diseases explained by differential gene expression be-
tween the zones
The prostate consist of several zones in which different diseases arise. Prostate 
cancer mainly occurs in the peripheral zone whereas BPH only appears in the 
transition zone. We investigated gene expression of the human prostate zones 
to explore why these different diseases originate from distinct zones. To date, 
most studies focused on gene expression profiling of prostate diseases and 
investigated the molecular variation of PC and BPH compared to normal tissue 
(1). Little attention has been given to the molecular bases of the prostate zones 
as possible explanation for the distinct occurrence of the prostate diseases. Us-
ing microarray technology, we demonstrated that there is differential expression 
between the two normal prostate zones (2). Evidence suggests that the difference 
in gene expression is not caused by a difference in quantity of certain cells, but 
by a qualitative distinction in cell type characteristics. This was demonstrated in 
Chapter 2, where frozen prostate sections of 9 patients were scored for quantity of 
stromal and epithelial cells. The average proportion of stromal and epithelial cells 
was approximately 50:50 and this equal distribution was alike in both transition 
and peripheral zone. Additionally, both zones were analyzed for expression of 
several stromal, epithelial, endothelial, neuro-endocrine and lymphocyte infiltra-
tion markers. There was no significant differential gene expression of these cell 
type markers between the prostate zones. 
Since quality of cell types is important in the prostate zone, it is important to 
study the interaction between stroma and epithelium, given that it is crucial in 
the progression of prostate cancer and BPH (3-5). Our data supports the view 
that cell characteristics of stroma and epithelium and with that, the interactions 
between stroma and epithelium, may already be different in the two normal zones. 
The major network that Ingenuity pathway analysis linked to the prostate zonal-
preferential genes was cell-to-cell signaling and interaction. Consequently, we 
speculate that differences in stromal-epithelial interactions between the prostate 
zones form the basis of susceptibility of the distinct prostate zonal diseases.
Gene expression of the family of forkhead transcription factors in the 
prostate
Forkhead transcription factors FOXF1 and FOXF2 were selected from microarray 
data for further study because they were higher expressed in the transition zone 
compared to peripheral zone. Not much was known about forkhead transcription 
factor expression (Fox) in the prostate and thus, to comprehend the potential 
role of Fox proteins in general, we first explored the expression of 12 differ-
ent Fox genes in different prostate tissues, including normal prostate, primary 
prostate cancer, androgen-dependent and independent xenografts and several 
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cell lines (6). Most of the 12 Fox genes are not markedly expressed in prostate, 
but FOXF1, FOXF2, FOXD1, FOXC1 and FOXA1 are distinctly expressed in 
the prostate (Chapter 3). FOXF2 is our main focus, because we discovered that 
its expression was significantly down-regulated in prostate cancer and proved 
to be stroma-specific. This gave FOXF2 a potential role as anti-tumor protein 
since it was highly expressed in the transition zone compared to the tumor-
prone peripheral zone.  Interestingly, its expression was elevated in androgen-
independent xenografts, which also suggests a role for FOXF2 in epithelial to 
mesenchymal transition (EMT).  In this thesis, we focused on PC rather than 
BPH, however, it would be interesting to further elucidate the role of FOXF2 in 
BPH, since we observed high expression of this gene in this disease, however, 
this can also be explained by the simple fact that BPH arises in the transition 
zone (6). Possibly, it can explain the benign characteristics of this transition zonal 
disease compared to the malignant qualities of PC in peripheral zone, where 
FOXF2 is lower expressed.
Exploration of potential target genes of FOXF2
To investigate the functional relevance of FOXF2, we elucidated its target genes 
and functional pathways (chapter 4). To achieve this, siRNA experiments were 
performed and evaluated by microarray analyses, in which we compared PrSC 
cells treated with negative control siRNA and siRNA directed against FOXF2. 
Several pathways, i.e. PDGF signaling, PPAR signaling, PI3K/AKT signaling, 
integrin signaling, VEGF signaling and actin cytoskeleton signaling were found 
in the microarray studies. FOXF2 was discovered to regulate extracellular matrix 
(ECM)) and cytoskeletal proteins, which pinpointed a role for the FOXF2 pathway 
to cellular assembly and organization.  Enhanced production and activation of 
extracellular matrix proteins has been described in prostate carcinoma (7) and 
the following sections will discuss the role and involvement of FOXF2 in ECM 
modeling together with other ECM-associated proteins to further unravel the 
molecular basis of prostate diseases.
FOXF2 and its role in extracellular matrix remodeling
Molecular insights into signaling pathways and regulators of ECM proteins in the 
prostate and prostate cancer are beginning to emerge. Matrix metalloproteinases 
(MMPs) are Zn(2+) binding endopeptidases that break down a variety of compo-
nents of the ECM. These proteins are regulated in normal and pathologic tissue 
remodeling processes, such as wound healing, angiogenesis and tumor invasion. 
The latter is of great importance since MMPs are involved in prostate cancer 
matrix invasion and metastasis (7). In microarray analyses, several components 
and regulators of the ECM were found to be down-regulated by FOXF2. One of 
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the genes down-regulated by FOXF2 was MMP1. Furthermore, tissue inhibitor 
of metalloproteinase 3 (TIMP3) was found to be up-regulated by FOXF2, which 
is reported as inhibitor of MMPs. The balance between MMPs and TIMPs regu-
lates remodeling of the extracellular matrix (ECM) and FOXF2 seems to play a 
role in adapting the ECM in this balance (8). It is of importance to discuss ECM 
signaling and its relation to FOXF2 in combination with prostate cancer.
The balance between MMPs and TIMPs regulates remodeling of the ECM (9). 
A scheme from Biocarta (www.biocarta.com) illustrates an example of ECM 
signaling (Figure 1). We propose that FOXF2 could initiate a similar signaling 
cascade since we found several related genes in our microarray analysis. We 
found TIMP3 up-regulated by FOXF2, which inhibits MMP2 in the scheme, but 
is able to suppress several other MMPs as well (8). 
Figure 1. Regulation of extracellular matrix proteins
CXCL12, a target gene of FOXF2
CXCL12 was highly up-regulated by FOXF2 in the prostate stromal cells. Since 
CXCL12 is implicated in promoting prostate cancer metastasis it might link the 
FOXF2 pathway to cancer. To address this, we analyzed the expression of this 
gene in normal prostate, primary prostate tumors and prostate cancer metastases 
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in a large cohort of prostate cancer patients (Chapter 4). CXCL12 was higher 
expressed in normal prostate versus prostate cancer and it was elevated in PC 
lymph node metastases. CXCL12 is thought to advance prostate cancer progres-
sion in later stages (10). CXCL12 is described to regulate several MMPs in dif-
ferent prostate cancer cell lines, which potentiate tissue invasion and penetration 
of basement membranes by metastatic prostate cancer cells (11,12). In normal 
prostate environment, CXCL12 is higher expressed than in primary prostate 
tumors, where it possibly regulates prostate stroma homeostasis by regulating 
ECM remodeling. In later stages of prostate cancer, CXCL12 might switch into 
a tumor promoter and, next to FOXF2, play a role in EMT. It appears that these 
two proteins have an inhibitory role in normal stroma, but in later stages, are able 
to obtain the ability to interconverse epithelial cells into cells with mesenchymal 
characteristics. 
FOXF2 and its role in regulating metallothioneins 
Metallothioneins (MTs) have been reported to be differentially expressed in 
tumors and a specific role for MTs in prostate oncogenesis was suggested by 
Moussa et al (13,14). We found that FOXF2 siRNA treatment resulted in up-regu-
lation of most MTs, like MT1E, MT2a, MT1F, MT1G, MT1H and MT1X within the 
metallothionein gene locus on chromosome 16. MTs are a family of low molecular 
weight, heavy metal-binding proteins characterized by a high cysteine content 
and lack of aromatic amino acids (15). In mammals, the cysteine residues are 
absolutely conserved and serve to coordinate heavy metal atoms such as zinc, 
cadmium, and copper via mercaptide linkages. These qualities provide protec-
tion against toxic metals and oxidative stress, and by controlling the cellular zink 
levels, it is offering a protective role in apoptosis. In carcinogenesis, high MT 
expression was linked to increased cell proliferation and less apoptotic cells (16). 
The tumor stroma may react to tumor growth and aggressiveness by the expres-
sion of MTs and consequently develops a resistance to apoptosis. The process 
of carcinogenesis is related to a failure in immune response against cancer cells 
that enables tumor progression and dissemination. This cancer-specific suppres-
sion is crucial for tumor survival. The evaluation of MT expression in cancer and 
its stroma seems to correlate with the level of immune system inhibition. To this 
point, many genes of the MT and MMP families were found to be down-regulated 
by FOXF2. Given that FOXF2 is higher expressed in the transition zone, in which 
prostate tumors are infrequent and less aggressive as compared to peripheral 
zone tumors, we suggest that FOXF2 controls normal prostate homeostasis, 
among others by regulating MT and MMP function. 
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FOXF2 and TGFβ opposing pathways?
Analysis by Gene Set Enrichment Analysis (GSEA) revealed that a significant 
number of FOXF2 up-regulated genes were down-regulated when the same 
PrSC cells were treated with TGFβ3 (17), indicating that FOXF2 and TGFβ3 
are opposing pathways. Current investigations demonstrate that TGFβ plays 
key roles in prostate carcinogenesis by regulating tumor initiation, progression 
and metastasis through a diverse repertoire of tumor-cell-autonomous and host-
tumor interactions (18). It can operate as both suppressor and activator. TGFβ 
signaling in stromal fibroblasts can suppress tumorigenesis in adjacent epithelium 
whereas it can promote invasion and metastasis during later stages of carcinoma 
progression. TGFβ-mediated regulation is highly complex and plays a variety of 
roles in numerous networks (19). TGFβ was described to be involved in EMT in 
cancer development and progression and it stimulates these phenomena, among 
others, via MMP-dependent mechanisms (20-22). MMP28 is able to induce EMT 
and cell invasion through TGFβ dependent mechanism in lung carcinoma cell 
and in normal mammary epithelial cells TGFβ was reported to be an inducer of 
EMT as well (23,24). Furthermore, TGFβ is involved in disintegration of cell-cell 
adhesions, cytoskeletal remodeling and cell-matrix adhesion (25-31). The latter 
feature involves remodeling of the cell contact with basal lamina and engages 
activation of matrix metalloproteinases, MMP2 and MMP9, which are regulated 
by TGFβ. The basal lamina is a specialized ECM structure, composed of collagen 
type IV, laminin and nidogen. Increased synthesis of MMPs in response to TGFβ 
leads to degradation of collagen type IV. As will be discussed below, several of 
these proteins are also regulated by Foxf2 in prostate development and thus 
again suggest a connection between these two pathways. In addition, in GSEA 
analyses, a significant correlation was identified between genes up-regulated by 
both FOXF2 and TGFβ3. Since both FOXF2 and TGFβ are implicated in EMT it 
may be that they share these common pathways to initiate EMT. 
FOXF2 and stroma-epithelial interactions
An important manifestation in prostate tumor progression is the presence of 
reactive stroma. This is the reactive connective tissue located in most malignant 
tumors that surrounds the infiltrating tumor cells. It mainly consists of activated 
myofibroblastic cells and an altered extracellular matrix (ECM) (34). The stromal 
changes are the result of interactions during tumor progression between ma-
lignant cells, ECM, and the fibroblasts that normally populate the connective 
tissue, and involve also inflammatory cells and blood vessels. In breast carci-
noma, paracrine factors such as platelet derived growth factor (PDGF) (35) and 
TGFβ (36,37) secreted by the tumor cells, could initiate formation of reactive 
stroma. In view of the fact that we found FOXF2 to be a stromal transcription 
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factor regulating, among others, ECM proteins and PDGFA, and is associated 
with TGFβ, it is possible that FOXF2 is involved in controlling reactive stroma 
formation in transition zone. 
The role of Foxf2 in prostate development
Comprehension of mammalian prostate development and function will result 
in a better understanding of prostate cancer. FOXF2 is higher expressed in the 
transition zone, its expression is stroma specific and it is higher expressed in 
normal prostate compared to prostate cancer (2). In addition, a role for FOXF2 
was suggested in EMT (6). After exploring FOXF2 gene expression and FOXF2 
regulated pathways in human adult prostate in previous studies (chapter 4), 
we wanted to identify the potential role for Foxf2 in prostate development. The 
preliminary role of Foxf2 was investigated in mouse prostate development and 
we observed that the stroma compartment in Foxf2 knockouts showed less ex-
tracellular eosinofilic matrix, suggesting a role for Foxf2 in attachment of proteins 
to the cell matrix. Furthermore, the stroma appeared disorganized and epithelial 
cells in the prostate ducts also look disordered in Foxf2 knockout mice. Metal-
lothionein staining showed higher protein expression in the urogenital sinus of 
Foxf2-/- knockout compared to wild-type mice.  Another interesting phenomenon 
is that Foxf2-/- knockout mice give rise to a phenotype, in which the Foxf2 mutants 
develop a cleft in the secondary palate. An important EMT event in development 
is formation of the secondary oral palate, in which differentiated epithelial cells 
undergo an EMT and so become integrated into the mesenchymal compart-
ment, thereby completing the program of palatogenesis (32). It appears that 
these Foxf2-/- mice are unable to undergo this last stage of EMT because they 
are lacking Foxf2. This strengthens the idea that in adult life FOXF2 is involved 
in EMT since it is known that highly conserved EMT programs are implicated 
in tumor progression (33). This is in concurrence with the results we found in 
human prostate cells and once more indicates a very important role for FOXF2 
in regulating prostate stroma homeostasis and EMT.
FOXF2, a role in epithelial to mesenchymal transition?
Carcinoma invasion of epithelial cancers usually is accompanied by the loss of an 
epithelial phenotype and acquisition of a fibroblastic or mesenchymal phenotype, 
referred to as epithelial tot mesenchymal transition (EMT). EMT is a crucial step 
in conversion of early stage to invasive cancer. MMPs are correlated to poor 
prognosis and linked to EMT in various diseases (38-41). Since FOXF2 is highly 
expressed in androgen-independent xenografts and is suggested to regulate 
several ECM proteins, it appears to be involved in EMT. So, this important transi-
tion step from early primary tumors to invasive and metastatic tumors, might be 
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regulated by FOXF2. Supporting this, as described above, is the fact that Foxf2 
knockout mice have a defective formation of the secondary cleft palate, which 
indicates that Foxf2 is involved in this EMT event during prostate development. 
All members of the TGFβ super family have been reported as major induction 
signals of EMT, although the precise signaling pathways may differ during various 
EMT events. It could well be that in EMT events in the prostate, FOXF2, next to 
TGFβ, is involved in this signaling, as they share a significant overlap between 
genes up-regulated in TGFβ3 treated PrSC cells. Interestingly, TGFβ3 knockout 
mice present a cleft palate phenotype, similar to the phenotype in Foxf2 knockout 
mice, and it has been described that TGFβ3 originally has a role in initiating EMT 
in secondary palate fusion (32). 
In the majority of human carcinoma cell population, loss of E-cadherin is common 
in cells that have previously passed EMT. Various EMT-inducing transcription 
factors, including Snail, Slug, Twist1, FOXC2, ZEB and Goosecoid have been 
recognized in tumor invasion and metastasis in a variety of tissues.  FOXF2 can 
possibly be such a transcription factor for EMT in the prostate. Next to EMT, 
earlier mentioned transcription factors have also been described in cancer stem 
cells (CSCs) (42). It has been suggested that these CSCs are responsible for 
driving tumor growth and metastasis. It was demonstrated that mammary stem 
cells, with special CD44high/CD24low antigenic phenotype which characterized 
these CSCs, express EMT markers (43). 
Future perspectives
The results described in this thesis revealed that FOXF2 plays an important role 
in the prostate. Exploration of conditional Foxf2 knockouts in various adult mice 
PC models would be very informative to further elucidate the function of Foxf2. 
We hypothesize that knockout of Foxf2 in, for instance Pten knockout mice will 
lead to earlier tumor initiation and progression. Furthermore, we speculated that 
FOXF2 is involved in EMT. We analyzed gene expression of FOXF2 in a small 
amount of prostate cancer lymph node metastasis samples, but saw no elevated 
expression. However, it is necessary to determine the level of gene expression of 
FOXF2 in many more samples. If we can find elevated gene expression of FOXF2 
in lymph node metastases it would strengthen its role in EMT. Since we studied 
the role of FOXF2 in stroma cells, the next step would be to analyze its role in 
epithelial prostate cancer cells by overexpressing FOXF2 in these cells. This 
will depict regulation of pathways in both stroma and epithelium and so further 
completes understanding of the role of FOXF2 in prostate cancer progression. 
Additionally, we could analyze EMT markers in these epithelial cells and evalu-
ate these cells for presence of CD44+/α2β1+/CD133+ cancer stem cell phenotype 
in the prostate. Besides gene expression analyses, we attempted to investigate 
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FOXF2 protein expression by western blot and immunohistochemistry analyses. 
It is essential to determine expression and localization of FOXF2 in tissues and 
cell lines at the protein level and we have put a lot of effort into this. Unfortunately, 
we were unsuccessful in reliably establishing these techniques with commercial 
available antibodies for visualizing these FOX proteins. For future experiments, 
serious investments into development of FOXF2 antibodies have to be made. In 
this thesis we focused on PC rather than BPH. We observed somewhat higher 
expression of FOXF2 in BPH than in transition zone. It would be very informative 
to study the role of FOXF2 in BPH in clinical prostate samples and demonstrate 
its possible involvement in the development of this disease.
In conclusion, FOXF2 has a unique stroma-specific expression in developing and 
adult prostate tissues. From mouse knockout experiments it appears that Foxf2 
is vital for normal tissue development. FOXF2 seems to have an inhibitory role 
in normal stroma, where it is thought to regulate prostate homeostasis in transi-
tion zone via several ECM proteins, CXCL12, TGFβ and MTs. This suppressive 
role of FOXF2 might explain the predisposition of PC and BPH. However, next to 
these tumor inhibiting qualities, in later stages, FOXF2 appears able to obtain the 
ability to interconverse epithelial cells into cells with mesenchymal characteristics. 
This possible capacity of controlling EMT by FOXF2 may involve CXCL12 and 
TGFβ. Next to actively participating in tumor growth and progression, the stroma 
seems to have tumor suppressive qualities as well. 
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Summary
Prostate cancer is second only to lung cancer as a cause for tumor-related deaths 
among men. Approximately 80% of 80 year old men suffer from prostate cancer, 
however not all these carcinomas pose a threat to life or health. The prostate 
consist of several zones, the transition, peripheral and central zone. Prostate 
cancer mainly occurs in the peripheral zone whereas benign prostatic hyper-
plasia (BPH) only occurs in the transition zone. BPH is a benign enlargement of 
the prostate and a common condition among aging men. We hypothesized that 
underlying gene expression will explain the confinement of these diseases to 
the transition and peripheral zone. In Chapter 1, gene expression profiling of the 
human prostate zones was performed by microarray analyses. 346 genes were 
differentially expressed between the prostate zones, which means that 346 genes 
were higher or lower expressed in one of the two zones. Few of the transition 
zone-specific genes, including FOXF1, FOXF2, COCH, ASPA and FLJ10970, 
were also observed to be stroma-specific and were not expressed in epithelial 
cells. This suggests that stroma-epithelial communication is different between 
the prostate zones. The forkhead transcription factor family was analyzed in the 
prostate to investigate its role in prostate and prostate disease. In Chapter 3, 
we investigated gene expression of 12 different forkhead transcription factors. 
Gene expression was analyzed in the prostate zones, prostate cancer, lymph 
node metastases, BPH, xenografts and several prostate cell lines. Expression of 
FOXA1, FOXC1, FOXD1, FOXF1 and FOXF2 was higher expressed in certain 
tissues. Markedly, FOXA1 and FOXC1 appear to have opposing function, where 
FOXA1 is mainly expressed in androgen dependent cell lines and xenografts, 
while FOXC1 is primarily expressed in androgen independent cell lines and xe-
nografts. FOXD1 was higher expressed in prostate cancer compared to normal 
prostate, while FOXF1 and FOXF2 were lower expressed in prostate cancer 
compared to normal tissue.
Since FOXF2 is lower expressed in prostate cancer and higher in transition zone, 
is stroma-specific and linked to epithelial to mesenchymal transition (EMT) in 
prostate cancer xenografts, we further investigate its role in prostate function. 
Chapter 4 describes the target genes of FOXF2 that we identified by comparing 
microarray expression profiles of primary prostate stroma cells (PrSC) treated 
with control or siRNA directed against FOXF2. We found that extracellular matrix 
proteins, metallothioneins and CXCL12 were regulated by FOXF2. Furthermore, 
TGFβ seems to play an important role next to FOXF2. FOXF2 appears to control 
normal prostate homeostasis by regulating these proteins. The fact that prostate 
cancer occurs less frequent in the transition than the peripheral zone could be 
explained by the fact that FOXF2 regulates homeostasis more prominent in this 
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zone compared to the peripheral zone. In this respect, FOXF2 appears to have 
a tumor suppressive function.
In Chapter 5 we investigated prostate development in Foxf2 knockout mice. We 
compared the urogenital sinus in wild-type mice and Foxf2 knockout mice. In 
Foxf2 knockouts the stromal compartment showed less eosinofilic extracellular 
matrix, which indicates a role for Foxf2 in attachment of proteins to the cell-
matrix. Proteins like laminin and metallothionein, which have been discussed in 
chapter 4, are higher expressed in Foxf2 knockout mice compared to wild-type. 
This confirms the idea that Foxf2 is involved in stroma regulation. In Chapter 
6, the findings of these studies are discussed with a focus on prostate zones, 
prostate diseases and the potential role of FOXF2.
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Samenvatting
Prostaatkanker is, na longkanker, de meest frequente doodsoorzaak aan kanker 
in de Westerse wereld. Bijna 80% van mannen van 80 jaar heeft prostaatkanker, 
echter lang niet al deze mannen zullen aan prostaatkanker overlijden. 
De prostaat bestaat uit verschillende zones, de transitie, de perifere en de cen-
trale zone. Prostaatkanker wordt voornamelijk gevonden in de perifere zone, 
terwijl benigne prostaat hyperplasie (BPH) exclusief te vinden is in de transitie 
zone. BPH is een goedaardige zwelling van de prostaat die lijdt tot plasklachten 
bij oudere mannen. Omdat prostaatkanker en BPH preferentieel gelokaliseerd 
zijn in een bepaald deel van de prostaat, hebben wij als hypothese gesteld, dat 
onderliggende genexpressie van de verschillende prostaatzones de voorkeurslo-
catie van de ziektes kan verklaren. In Hoofdstuk 2 zijn genexpressie profielen 
bepaald van de perifere en transitie zone met behulp van microarray analyses. 
346 genen kwamen differentieel tot expressie, wat betekent dat 346 genen ho-
ger of lager tot expressie komen in een van de twee zones.  Een aantal van de 
genen die hoger tot expressie komen in de transitie zone zoals FOXF1, FOXF2, 
COCH, ASPA en FLJ10970, bleken preferentieel in prostaat stroma cellen aan 
te staan en niet tot expressie te komen in prostaat epitheliale cellen. Dit sug-
gereert dat de communicatie tussen het stroma en epitheel anders is tussen de 
twee zones. De familie van forkhead transcriptie factoren werd in de prostaat 
onderzocht om een idee te krijgen welke leden van deze familie een mogelijke 
rol zouden kunnen spelen in prostaat en prostaatziekte ontwikkeling.
In Hoofdstuk 3 wordt de genexpressie van 12 verschillende forkhead transcriptie 
factoren in de prostaat besproken. Deze expressie werd getest in verschillende 
weefsels, zoals normaal prostaatweefsel, prostaatkanker, prostaatkanker lym-
feklier metastasen, prostaat xenografts en verschillende prostaat cellijnen. We 
zagen dat expressie van FOXA1, FOXC1, FOXD1, FOXF1 en FOXF2 hoger 
tot expressie kwamen in bepaalde weefsels. Een opvallende observatie is dat 
FOXA1 en FOXC1 een tegengestelde functie lijken te hebben, waarbij FOXA1 
juist hoger tot expressie komt in androgeen afhankelijke cellijnen en xenografts, 
terwijl FOXC1 juist in androgeen onafhankelijke cellijnen en xenografts hoger tot 
expressie komt. FOXD1 kwam hoger tot expressie in prostaatkanker vergeleken 
met normaal weefsel, terwijl FOXF1 and FOXF2 juist lager tot expressie kwamen 
in prostaatkanker. 
Omdat FOXF2 lager tot expressie komt in prostaatkanker en juist hoger in de 
transitie zone, het een stroma-specifiek eiwit is en in prostaatkanker xenografts 
met epitheel-mesenchymale transitie (EMT) geassocieerd werd, wilden we meer 
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leren over de rol van FOXF2 in de prostaat. In Hoofdstuk 4 beschrijven we de 
targetgenen van FOXF2, die we gevonden hebben door FOXF2 in primaire pros-
taat stroma cellen uit te zetten, door middel van siRNA studies. Met behulp van 
microarray analyses konden we achterhalen welke genen gereguleerd worden 
door dit eiwit.  We vonden dat extracellulaire matrix eiwitten, metallothionein eiwit-
ten en CXCL12 gereguleerd worden door FOXF2. Ook TGFβ lijkt een belangrijke 
rol te spelen naast FOXF2. De belangrijke regulerende rol van het stroma in de 
prostaat wordt door deze bevindingen beduidend verstrekt en het lijkt erop dat 
FOXF2 de kwaliteit bezit om het stroma in evenwicht te houden. Dat er in de 
transitie zone, waarin FOXF2 hoger tot expressie komt dan in de perifere zone, 
minder prostaatkanker voorkomt, zou kunnen worden verklaard door het feit dat 
FOXF2 de homeostase hier beter kan regelen dan in de perifere zone. In dat 
opzicht lijkt FOXF2 dus een tumorremmende functie te hebben.
In Hoofdstuk 5 onderzochten we de ontwikkelende prostaat in Foxf2 knockout 
muizen. Dit is gedaan door de urogenitale sinus te vergelijken in normale mui-
zen met Foxf2 knockout muizen. In Foxf2 knockout muizen is de stuctuur van 
de extracellulaire matrix aangedaan, het stroma is veranderd en eiwitten als 
metallothionein en laminin, die we ook in Hoofdstuk 4 besproken hebben, komen 
hoger tot expressie in Foxf2 knockout muizen vergeleken met normale muizen. 
Ook hier is dus een duidelijk indicatie dat FOXF2 een rol speelt in stroma regu-
latie. In Hoofdstuk 6 worden de bevindingen van deze studies bediscussieerd, 
waarin de prostaatzones en bijbehorende ziektes en de rol van FOXF2 in de 
prostaat centraal staan.
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Het dankwoord, het is waarschijnlijk het meest gelezen stukje van een proefschrift 
en niet het onbelangrijkste stuk, want er zijn een heleboel mensen betrokken 
bij het tot stand komen van zo’n boek. Niet alleen op wetenschappelijk gebied, 
maar juist aan het thuisfront.
Allereerst wil ik mijn co-promotor Guido bedanken voor de wetenschappelijke 
begeleiding van de afgelopen vijf jaar. Guido, ik heb veel van je geleerd. Het 
heeft even geduurd voordat het project echt van de grond kwam, maar uiteindelijk 
hebben we heel interessante dingen gevonden. Ik hoop dat je het project in de 
toekomst nog zult voortzetten. 
Mijn promotor Chris Bangma, bedankt voor het zorgvuldig lezen van het manu-
script.
Theo van der Kwast, met u heb ik heel wat prostaatplakken bekeken en geanaly-
seerd. Het is me een waar genoegen u in mijn commissie te mogen treffen. Ik 
heb met veel plezier met u samen gewerkt. De leukste tijd heb ik gehad toen ik 
met Dennis, Rute, Gert-Jan en Karin in de AIO-kamer zat. We hebben heel veel 
lol gehad samen en ik heb genoten van onze appelflap-eating-meetings. 
Rute, we hebben veel met elkaar kunnen delen, vooral leuke dingen, maar ook 
de mindere kanten van de wetenschap. Veel succes met de laatste loodjes, 
je hebt het verdiend! Als succesvolle post-doc, mama en binnenkort ook nog 
getrouwd, heb je het goed voor elkaar! 
Karin, we hebben veel dezelfde dingen meegemaakt de afgelopen jaren: trou-
wen, een dochtertje, bijna dezelfde baan ... Ik hoop dat je je dromen kunt 
waarmaken. 
Gert-Jan, dank je voor je gezelligheid, de koffiepauzes en je passie voor fo-
tografie. Je hebt me aangestoken met het fotografievirus. 
Dennis, jij mag altijd langskomen om mijn schouders te masseren in stressvolle 
tijden . Ik wens je heel veel geluk en succes toe in de toekomst. 
Peter, je hebt me ontzettend op weg geholpen bij het analyseren van microarray 
data. Je was een expert met alle beschikbare tools en ik heb met veel plezier 
met je samengewerkt. 
Hanneke, bedankt voor alle hulp bij het verzamelen van de data voor hoofdstuk 
vijf. Helaas heeft het (nog) niet geleid tot een publicatie, maar we hebben er wel 
leuk contact aan overgehouden. 
Marcel, bedankt voor het snijden van alle parafine coupes van de Foxf2-knockout-
muizen. 
Tar, je hebt me gered uit een bijna onmogelijke (grafische) situatie. Ik vind het 
fantastisch dat je me zo goed geholpen hebt en wil je op deze manier extra 
bedanken.
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Er zijn nog vele andere collega’s die ik wil bedanken voor hun gezelligheid, hulp 
bij experimenten of bioinformatica: Angelique, Don, Antoine, Wilma, Natasja, 
Joke, Flip, Rajesh en natuurlijk alle andere labcollega’s van Urologie. 
Carl, de laatste keer dat ik je sprak was bij de Vliegende Panters in het theater. 
Het stemt mij droevig dat je er niet bij zult zijn.
Niet minder belangrijk voor mij was het thuisfront en mijn vrienden, die er altijd 
vertrouwen in hadden dat ik het boekje afkreeg.
Tala, bedankt voor je trouwe mailtjes en je interesse, dat deed me altijd goed. 
Vera, we hebben fijne gesprekken gehad wanneer het weer even tegenzat. 
Yvonne, bedankt voor je begrip en medeleven al die jaren.
Bij jullie kon ik altijd alles weer even van me afzetten. 
David, ik vind het een eer dat je mijn paranimf wilt zijn. En natuurlijk ook Dennis, 
Petr, Wouter, Simone, Adriaan, Janice, Raoul, Iva, Karin, Eric, Edith en Marc: 
bedankt voor de interesse die jullie in mij bleven tonen. Ik hoorde jullie af en 
toe denken: is ze nu nog steeds niet klaar?! Het spijt me als ik jullie af en toe 
verwaarloosd heb het laatste jaar. Jeanette tack så mycket.
Mariska, ik ben trots dat jij zometeen naast me staat als paranimf en ik ben je 
dankbaar dat je altijd zo’n rotsvast vertrouwen in mij hebt gehad.
Ria, jij hebt vanaf het begin in mij geloofd en nooit getwijfeld aan mijn capaciteiten. 
Dit is mij erg dierbaar. Ik vind het een ongelofelijk gemis dat we dit niet samen 
met Ton kunnen delen, daarom heb ik dit boekje aan hem opgedragen.
Ton, ik mis je.
Papa en mama, jullie onvoorwaardelijk geloof en vertrouwen in mij hebben mij 
gebracht waar ik nu ben gekomen. Ik heb altijd de vrijheid gekregen om mijn 
eigen keuzes te maken en jullie hebben me daar altijd in gesteund. Ik kan niet 
in woorden uitdrukken hoeveel dit voor mij betekent. Ik hou van jullie.
Lieve Katie, hoewel je nog niet beseft wat dit proefschrift voor jouw mama betekent, 
heb je er nu al een grote bijdrage aan geleverd. Je bent het zonnetje in mijn leven 
en samen met je papa het grootste geluk dat ik ken. Alle onoverkomelijkheden 
verdwijnen als sneeuw voor de zon als jij naar je mama lacht.
Rem, jou kan ik onmogelijk bedanken met een paar woorden in een boekje. 
Zonder jou had ik hier nooit gestaan. Je bent echt mijn rots geweest, waarop ik 
altijd weer kon terugklauteren als ik even weggleed in de branding. Dank je wel 
voor je steun, je geduld en het begrip voor mijn onacceptabele werktijden het 
afgelopen jaar. Zonder jou was ik nooit zover gekomen. 
Ik hou van je!
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On a cloudy day
Come away with me
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